≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

Problems related to care-provider dependency

Endpoint Browser

Z21_PROBL_RELATED_CARE__DEPENDENCY

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Z74
  • Cause of death: ICD-10 — Z74

2 out of 7 registries used, show all original rules.

307

4. Check minimum number of events

None

307

5. Include endpoints

None

307

6. Filter based on genotype QC (FinnGen only)

301

Control definitions (FinnGen only)

Control exclude
Z21_PERSONS_ENCOUNTERI_HEALTH_SERVI_OTH_CIRCUMSTANC1

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
Z7

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 301 127 174
Unadjusted period prevalence (%) 0.07 0.05 0.08
Median age at first event (years) 76.05 75.79 76.25

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
307
Matched controls
3070
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Z74.0
ICD-10 Finland
Need for assistance due to reduced mobility
+∞
137.0
121
*
Z74.2
ICD-10 Finland
Need for assistance at home and no other household member able to render care
+∞
74.0
68
*
Z74.1
ICD-10 Finland
Need for assistance with personal care
+∞
56.0
52
*
Z74.8
ICD-10 Finland
Other problems related to care-provider dependency
+∞
46.0
43
*
Z75.5
ICD-10 Finland
Holiday relief care
+∞
43.8
41
*
N03AG01
ATC
valproic acid; systemic, rectal
9.5
38.3
49
60
N05AH03
ATC
olanzapine; systemic
8.5
30.5
42
56
A29
ICPC
General symptom/complaint other
4.5
29.0
90
260
N05AX08
ATC
risperidone; systemic
4.7
28.1
80
216
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
4.7
25.4
70
183
Z74.9
ICD-10 Finland
Problem related to care-provider dependency, unspecified
+∞
24.3
23
*
A28
ICPC
Limited function/disability NOS
3.5
24.3
123
492
SPAT1229
SPAT
Assessment of need for aid
4.9
23.5
58
138
R51
NOMESCO Finland
Aids services
+∞
23.2
22
*
SPAT1222
SPAT
Counselling/guidance promoting independent living
3.7
22.8
95
333
A06AD11
ATC
lactulose; oral
3.3
21.0
107
424
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
4.3
20.9
63
175
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
6.1
20.6
38
69
N05AH04
ATC
quetiapine; oral
3.7
20.0
79
265
L89
ICD-10 Finland
Decubitus ulcer and pressure area
9.0
19.5
25
30
F03
ICD-10 Finland
Unspecified dementia
4.2
18.7
56
154
N02AA05
ATC
oxycodone; systemic
3.1
18.4
104
434
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.2
17.6
91
359
SPAT1262
SPAT
Handing over of treatment supplies
3.3
17.4
82
306
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
17.3
149
775
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
5.7
17.2
34
66
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.2
16.8
86
337
307
Kela drug reimbursment
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
4.0
16.7
53
152
WX704
NOMESCO Finland
Intubation
4.9
15.7
37
84
N05BA04
ATC
oxazepam; oral
2.8
15.6
111
518
N05AA02
ATC
levomepromazine; systemic
6.2
15.2
27
47
N03AE01
ATC
clonazepam; systemic
5.3
14.4
30
61
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
3.3
14.3
62
218
CA1ME
NOMESCO Finland
Ultrasound oculometry
25.2
14.0
19
8
WZC00, ,
SPAT
3.5
13.9
55
182
N05AD01
ATC
haloperidol; systemic
5.5
13.9
28
55
N05BA06
ATC
lorazepam; systemic, sublingual
4.5
13.3
34
82
G40.9
ICD-10 Finland
Epilepsy, unspecified
5.8
13.3
25
46
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
4.8
13.2
31
70
SPAT1245
SPAT
Provision of support and information to patient’s family members
4.4
13.0
35
88
N30.0
ICD-10 Finland
Acute cystitis
3.0
12.6
65
252
K90
ICPC
Stroke/cerebrovascular accident
5.7
12.5
24
45
R53
ICD-10 Finland
Malaise and fatigue
2.5
12.3
106
534
N06AB04
ATC
citalopram; systemic
2.7
12.2
86
393
J01MA02
ATC
ciprofloxacin; systemic
2.4
12.2
152
902
N03AF01
ATC
carbamazepine; oral, rectal
4.2
12.2
34
88
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.9
12.2
38
107
SPAT1255
SPAT
Intravenous administration of medicine
3.9
12.0
37
103
R56.8
ICD-10 Finland
Other and unspecified convulsions
5.2
11.9
25
51
SPAT1249
SPAT
Treatment-related counselling outside office
2.4
11.8
123
674
P29
ICPC
Psychological sympt/compl other
5.0
11.6
26
56
N05BA01
ATC
diazepam; systemic, rectal
3.0
11.5
59
228
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
5.0
11.2
25
54
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.5
10.8
39
121
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
11.8
10.7
19
17
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.6
10.7
76
347
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
10.6
10.2
19
19
J01EA01
ATC
trimethoprim; systemic
2.3
10.1
109
599
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
2.3
10.0
99
524
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.2
9.9
134
805
C03CA01
ATC
furosemide; systemic
2.2
9.9
167
1094
N03AX12
ATC
[U] gabapentin; oral
2.7
9.9
58
240
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
4.0
9.9
29
78
G30.9
ICD-10 Finland
Alzheimer disease, unspecified
3.4
9.7
37
119
ZYC01, ,
SPAT
3.3
9.5
38
126
N05AX12
ATC
aripiprazole; systemic
12.9
9.5
16
13
Z74.3
ICD-10 Finland
Need for continuous supervision
+∞
9.4
9
*
WX892
NOMESCO Finland
Monitored bed care
3.4
9.4
35
111
A60
ICPC
General and Unspecified, Result test/procedure
4.2
9.2
25
63
K59.09
ICD-10 Finland
Constipation, unspecified
3.3
9.2
37
123
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
2.9
9.1
48
187
UKC02
NOMESCO Finland
Cystoscopy
2.3
8.7
78
392
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
8.6
92
498
WYA20
NOMESCO Finland
Home visit
4.3
8.4
22
54
XKW99
NOMESCO Finland
Other physiological examination of urinary or male genital system
9.9
8.4
16
17
Z75.0
ICD-10 Finland
Medical services not available in home
+∞
8.4
8
*
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
2.4
8.4
65
307
WX882
NOMESCO Finland
High dependency care
6.8
8.3
20
31
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.5
8.2
59
268
N03AX14
ATC
levetiracetam; systemic
7.6
8.1
18
25
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
3.6
8.0
27
80
F00.10*G30.1
ICD-10 Finland
Primary degenerative dementia of the Alzheimer's type, senile onset without additional symptoms
3.3
7.8
30
97
R1210
NOMESCO Finland
Medical assessment of need and possibilities to rehabilitation
18.9
7.7
11
6
SPAT1008
SPAT
Photography of fundus of the eye or interpretation of photograph
4.1
7.6
21
54
XA800
NOMESCO Finland
Neuropsychological investigation
4.6
7.5
18
41
A41.9
ICD-10 Finland
Sepsis, unspecified
3.8
7.5
23
64
N06AB06
ATC
sertraline; oral
3.0
7.4
35
128
Z75.8
ICD-10 Finland
Other problems related to medical facilities and other health care
+∞
7.3
7
*
ZYB04, ,
SPAT
30.8
7.2
9
*
WX725
NOMESCO Finland
Noninvasive ventilation
3.6
7.0
23
67
R5210
NOMESCO Finland
Assessment of the improvements needed in the living environment
14.2
6.9
11
8
SPAT1193
SPAT
Pap smear
4.4
6.8
17
40
G30.1
ICD-10 Finland
Alzheimer disease with late onset
2.4
6.8
50
229
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
41.0
6.8
8
*
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
3.9
6.8
20
54
S97
ICPC
Chronic ulcer skin
2.8
6.7
34
129
SPAT1252
SPAT
Overall medication plan or its review
2.9
6.7
32
118
WW200, ,
SPAT
2.0
6.6
83
472
G35
ICD-10 Finland
Multiple sclerosis
12.6
6.6
11
9
N06DX01
ATC
memantine; oral
2.3
6.6
56
273
SPAT1292
SPAT
Other function in accordance with SHToL (Finnish classification of nursing interventions)
2.5
6.6
42
180
R40.0
ICD-10 Finland
Somnolence
71.3
6.4
7
*
N05CD07
ATC
temazepam; oral
2.2
6.4
62
319
G20
ICD-10 Finland
Parkinson disease
3.7
6.3
20
57
Z76.8
ICD-10 Finland
Persons encountering health services in other specified circumstances
5.6
6.3
17
32
G91.2
ICD-10 Finland
Normal-pressure hydrocephalus
6.5
6.2
15
24
R33
ICD-10 Finland
Retention of urine
2.4
6.2
46
211
N03AX09
ATC
lamotrigine; oral
6.0
6.2
16
28
ZYC01
NOMESCO Finland
Remote contact by phone
3.9
6.2
18
48
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.2
6.1
60
310
SPAT1216
SPAT
Assessment of functional ability
2.1
6.1
63
332
NFQ20
NOMESCO Finland
Amputation of femur
6.9
6.1
14
21
M03BX01
ATC
baclofen; systemic
6.3
6.1
15
25

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
1.6e+00
2.0e+00
2.5e+00
3.0e+00
2.2e+00
2.0e+00
1.2e+00
cases:14.47%
controls:3.20%
cases:11.51%
controls:1.68%
cases:8.88%
controls:0.79%
cases:4.28%
controls:0.23%
cases:8.03%
controls:0.93%
cases:13.08%
controls:2.02%
cases:13.04%
controls:4.47%
44
97
260
2935
35
51
269
2981
27
24
277
3008
13
7
291
3025
24
28
275
2993
34
59
226
2867
21
98
140
2096
General symptom/complaint other
A29 [2002000163]
1.8e+00
2.3e+00
3.4e+00
—
3.2e+00
2.3e+00
1.4e+00
cases:12.17%
controls:2.18%
cases:9.87%
controls:1.06%
cases:5.59%
controls:0.20%
—
—
cases:6.02%
controls:0.26%
cases:11.54%
controls:1.23%
cases:13.04%
controls:3.56%
37
66
267
2966
30
32
274
3000
17
6
287
3026
—
18
8
281
3013
30
36
230
2890
21
78
140
2116
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
1.9e+00
2.2e+00
3.2e+00
—
2.3e+00
2.1e+00
2.5e+00
cases:5.92%
controls:0.92%
cases:6.25%
controls:0.73%
cases:3.95%
controls:0.16%
—
—
cases:2.68%
controls:0.26%
cases:5.77%
controls:0.72%
cases:10.56%
controls:0.96%
18
28
286
3004
19
22
285
3010
12
5
292
3027
—
8
8
291
3013
15
21
245
2905
17
21
144
2173
General Practice
1 [38004446]
1.8e+00
2.5e+00
2.6e+00
—
3.1e+00
2.4e+00
1.8e+00
cases:58.22%
controls:18.96%
cases:53.95%
controls:8.71%
cases:18.42%
controls:1.58%
—
—
cases:25.08%
controls:1.46%
cases:55.77%
controls:10.12%
cases:69.57%
controls:27.71%
177
575
127
2457
164
264
140
2768
56
48
248
2984
—
75
44
224
2977
145
296
115
2630
112
608
49
1586
Home Visit
OMOP4822459 [581476]
1.6e+00
2.1e+00
2.4e+00
2.5e+00
2.3e+00
1.6e+00
1.0e+00
cases:30.26%
controls:8.18%
cases:32.24%
controls:5.31%
cases:19.08%
controls:2.04%
cases:8.55%
controls:0.76%
cases:18.06%
controls:2.12%
cases:27.31%
controls:6.97%
cases:36.02%
controls:16.50%
92
248
212
2784
98
161
206
2871
58
62
246
2970
26
23
278
3009
54
64
245
2957
71
204
189
2722
58
362
103
1832
Limited function/disability NOS
A28 [2002000162]
1.6e+00
2.2e+00
2.4e+00
3.0e+00
2.3e+00
1.6e+00
7.2e-01
cases:18.09%
controls:4.29%
cases:19.41%
controls:2.54%
cases:11.51%
controls:1.12%
cases:5.92%
controls:0.30%
cases:11.04%
controls:1.22%
cases:15.38%
controls:3.55%
cases:15.53%
controls:8.25%
55
130
249
2902
59
77
245
2955
35
34
269
2998
18
9
286
3023
33
37
266
2984
40
104
220
2822
25
181
136
2013
pH of Urine by Test strip
5803-2 [3022621]
2.5e+00
3.2e+00
—
—
2.9e+00
2.6e+00
1.8e+00
cases:16.78%
controls:1.65%
cases:13.16%
controls:0.63%
—
—
—
—
cases:3.01%
controls:0.17%
cases:10.38%
controls:0.89%
cases:14.91%
controls:2.83%
51
50
253
2982
40
19
264
3013
—
—
9
5
290
3016
27
26
233
2900
24
62
137
2132
oxycodone; oral, parenteral
N02AA05 [21604260]
2.1e+00
2.5e+00
2.3e+00
—
2.2e+00
1.7e+00
1.0e+00
cases:8.55%
controls:1.12%
cases:10.20%
controls:0.96%
cases:5.26%
controls:0.53%
—
—
cases:3.68%
controls:0.43%
cases:7.69%
controls:1.54%
cases:12.42%
controls:4.92%
26
34
278
2998
31
29
273
3003
16
16
288
3016
—
11
13
288
3008
20
45
240
2881
20
108
141
2086
Specific gravity of Urine by Refractometry
5810-7 [3019150]
1.6e+00
2.2e+00
2.6e+00
—
2.1e+00
1.8e+00
8.8e-01
cases:21.05%
controls:5.31%
cases:18.09%
controls:2.51%
cases:6.58%
controls:0.53%
—
—
cases:4.68%
controls:0.60%
cases:16.92%
controls:3.35%
cases:21.74%
controls:10.30%
64
161
240
2871
55
76
249
2956
20
16
284
3016
—
14
18
285
3003
44
98
216
2828
35
226
126
1968
Emergency Room Visit
ER [9203]
9.0e-01
1.5e+00
1.5e+00
4.0e+00
1.1e+00
1.1e+00
8.7e-01
cases:59.21%
controls:37.04%
cases:42.11%
controls:14.35%
cases:8.22%
controls:1.98%
cases:8.22%
controls:0.16%
cases:5.69%
controls:1.95%
cases:33.46%
controls:14.35%
cases:60.87%
controls:39.56%
180
1123
124
1909
128
435
176
2597
25
60
279
2972
25
5
279
3027
17
59
282
2962
87
420
173
2506
98
868
63
1326
Neurology
13 [38004458]
1.7e+00
2.0e+00
2.3e+00
1.0e+50
1.6e+00
1.6e+00
8.8e-01
cases:44.08%
controls:12.43%
cases:26.32%
controls:4.75%
cases:8.22%
controls:0.86%
cases:2.30%
controls:0.00%
cases:3.68%
controls:0.73%
cases:21.92%
controls:5.30%
cases:29.19%
controls:14.63%
134
377
170
2655
80
144
224
2888
25
26
279
3006
7
0
297
3032
11
22
288
2999
57
155
203
2771
47
321
114
1873
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
8.5e-01
1.6e+00
2.6e+00
—
2.8e+00
1.2e+00
9.6e-01
cases:13.16%
controls:6.07%
cases:9.87%
controls:2.08%
cases:3.95%
controls:0.30%
—
—
cases:4.35%
controls:0.26%
cases:6.92%
controls:2.26%
cases:13.66%
controls:5.70%
40
184
264
2848
30
63
274
2969
12
9
292
3023
—
13
8
286
3013
18
66
242
2860
22
125
139
2069
lactulose; oral
A06AD11 [21600571]
1.6e+00
1.9e+00
1.9e+00
—
1.6e+00
1.6e+00
1.2e+00
cases:12.17%
controls:2.80%
cases:12.50%
controls:2.11%
cases:2.96%
controls:0.46%
—
—
cases:3.68%
controls:0.73%
cases:11.15%
controls:2.36%
cases:16.15%
controls:5.38%
37
85
267
2947
38
64
266
2968
9
14
295
3018
—
11
22
288
2999
29
69
231
2857
26
118
135
2076
clonazepam; oral, parenteral
N03AE01 [21604415]
2.1e+00
2.5e+00
—
—
—
2.6e+00
2.6e+00
cases:4.28%
controls:0.56%
cases:3.95%
controls:0.33%
—
—
—
—
—
—
cases:3.85%
controls:0.31%
cases:6.83%
controls:0.55%
13
17
291
3015
12
10
292
3022
—
—
—
10
9
250
2917
11
12
150
2182
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
1.4e+00
2.0e+00
2.7e+00
—
2.1e+00
1.5e+00
7.2e-01
cases:18.75%
controls:5.15%
cases:17.76%
controls:2.87%
cases:6.25%
controls:0.43%
—
—
cases:4.01%
controls:0.53%
cases:14.62%
controls:3.73%
cases:18.01%
controls:9.66%
57
156
247
2876
54
87
250
2945
19
13
285
3019
—
12
16
287
3005
38
109
222
2817
29
212
132
1982
Inpatient Hospital
21 [8717]
1.3e+00
1.7e+00
2.0e+00
—
1.9e+00
1.8e+00
1.1e+00
cases:70.39%
controls:40.17%
cases:49.01%
controls:15.34%
cases:17.43%
controls:2.70%
—
—
cases:15.38%
controls:2.68%
cases:48.85%
controls:14.01%
cases:60.87%
controls:34.73%
214
1218
90
1814
149
465
155
2567
53
82
251
2950
—
46
81
253
2940
127
410
133
2516
98
762
63
1432
olanzapine; oral, parenteral
N05AH03 [21604543]
2.4e+00
2.3e+00
—
—
—
2.4e+00
2.4e+00
cases:4.28%
controls:0.40%
cases:5.26%
controls:0.53%
—
—
—
—
—
—
cases:5.00%
controls:0.48%
cases:7.45%
controls:0.73%
13
12
291
3020
16
16
288
3016
—
—
—
13
14
247
2912
12
16
149
2178
Bacteria identified in Urine by Culture
630-4 [3026008]
1.3e+00
1.7e+00
2.3e+00
—
2.0e+00
1.4e+00
7.6e-01
cases:20.39%
controls:6.63%
cases:17.43%
controls:3.69%
cases:6.91%
controls:0.73%
—
—
cases:4.68%
controls:0.63%
cases:15.38%
controls:4.37%
cases:22.36%
controls:11.90%
62
201
242
2831
53
112
251
2920
21
22
283
3010
—
14
19
285
3002
40
128
220
2798
36
261
125
1933
Pneumonia, unspecified
J18.9 [45601123]
9.0e-01
1.8e+00
1.8e+00
—
2.2e+00
1.2e+00
1.5e+00
cases:9.54%
controls:4.12%
cases:11.18%
controls:2.01%
cases:2.30%
controls:0.40%
—
—
cases:2.34%
controls:0.26%
cases:7.31%
controls:2.22%
cases:28.57%
controls:7.93%
29
125
275
2907
34
61
270
2971
7
12
297
3020
—
7
8
292
3013
19
65
241
2861
46
174
115
2020
risperidone; oral, parenteral
N05AX08 [21604559]
1.8e+00
2.3e+00
2.1e+00
—
—
1.9e+00
1.2e+00
cases:5.26%
controls:0.89%
cases:7.89%
controls:0.89%
cases:3.29%
controls:0.40%
—
—
—
—
cases:7.69%
controls:1.23%
cases:9.94%
controls:3.24%
16
27
288
3005
24
27
280
3005
10
12
294
3020
—
—
20
36
240
2890
16
71
145
2123
citalopram; oral, parenteral
N06AB04 [21604712]
1.7e+00
1.8e+00
2.3e+00
—
—
1.9e+00
1.4e+00
cases:14.47%
controls:2.94%
cases:10.86%
controls:2.04%
cases:4.61%
controls:0.49%
—
—
—
—
cases:12.69%
controls:2.05%
cases:13.04%
controls:3.42%
44
89
260
2943
33
62
271
2970
14
15
290
3017
—
—
33
60
227
2866
21
75
140
2119
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
1.4e+00
2.0e+00
2.6e+00
—
1.7e+00
1.4e+00
6.8e-01
cases:21.71%
controls:6.13%
cases:19.74%
controls:3.27%
cases:6.91%
controls:0.53%
—
—
cases:4.35%
controls:0.83%
cases:16.15%
controls:4.68%
cases:21.12%
controls:11.94%
66
186
238
2846
60
99
244
2933
21
16
283
3016
—
13
25
286
2996
42
137
218
2789
34
262
127
1932
pregabalin; oral
N02BF02 [955152]
1.2e+00
1.5e+00
1.4e+00
—
1.8e+00
1.4e+00
1.3e+00
cases:10.86%
controls:3.59%
cases:7.89%
controls:1.91%
cases:3.29%
controls:0.79%
—
—
cases:3.68%
controls:0.63%
cases:6.92%
controls:1.81%
cases:13.04%
controls:3.92%
33
109
271
2923
24
58
280
2974
10
24
294
3008
—
11
19
288
3002
18
53
242
2873
21
86
140
2108
Handing over of treatment supplies
SPAT1262 [2001700363]
1.1e+00
1.1e+00
2.0e+00
—
2.0e+00
1.3e+00
1.0e+00
cases:14.47%
controls:5.51%
cases:8.22%
controls:2.94%
cases:3.62%
controls:0.49%
—
—
cases:3.68%
controls:0.50%
cases:10.00%
controls:2.80%
cases:13.66%
controls:5.38%
44
167
260
2865
25
89
279
2943
11
15
293
3017
—
11
15
288
3006
26
82
234
2844
22
118
139
2076
Emergency Room and Inpatient Visit
ERIP [262]
9.2e-01
1.9e+00
2.3e+00
—
2.3e+00
1.0e+00
5.6e-01
cases:12.50%
controls:5.41%
cases:18.09%
controls:3.23%
cases:5.92%
controls:0.63%
—
—
cases:4.01%
controls:0.40%
cases:11.54%
controls:4.58%
cases:19.88%
controls:12.44%
38
164
266
2868
55
98
249
2934
18
19
286
3013
—
12
12
287
3009
30
134
230
2792
32
273
129
1921
Limited function/disability (L)
L28 [2002000647]
8.6e-01
1.5e+00
2.8e+00
—
2.0e+00
1.3e+00
6.4e-01
cases:6.91%
controls:3.03%
cases:6.58%
controls:1.62%
cases:2.63%
controls:0.16%
—
—
cases:2.01%
controls:0.26%
cases:6.92%
controls:2.08%
cases:12.42%
controls:6.93%
21
92
283
2940
20
49
284
2983
8
5
296
3027
—
6
8
293
3013
18
61
242
2865
20
152
141
2042
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
1.2e+00
1.8e+00
2.3e+00
—
1.8e+00
1.4e+00
5.8e-01
cases:23.36%
controls:8.71%
cases:21.05%
controls:4.39%
cases:7.89%
controls:0.82%
—
—
cases:5.02%
controls:0.89%
cases:19.23%
controls:5.74%
cases:24.84%
controls:15.63%
71
264
233
2768
64
133
240
2899
24
25
280
3007
—
15
27
284
2994
50
168
210
2758
40
343
121
1851
Other function in accordance with SHToL (Finnish classification of nursing interventions)
SPAT1292 [2001700393]
1.2e+00
1.9e+00
2.3e+00
—
3.0e+00
8.0e-01
5.2e-01
cases:6.25%
controls:1.98%
cases:5.26%
controls:0.86%
cases:3.29%
controls:0.33%
—
—
cases:3.68%
controls:0.20%
cases:2.69%
controls:1.23%
cases:4.97%
controls:3.01%
19
60
285
2972
16
26
288
3006
10
10
294
3022
—
11
6
288
3015
7
36
253
2890
8
66
153
2128
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
9.9e-01
1.4e+00
2.4e+00
—
2.1e+00
1.3e+00
7.6e-01
cases:19.08%
controls:8.08%
cases:14.14%
controls:3.86%
cases:5.59%
controls:0.53%
—
—
cases:5.35%
controls:0.66%
cases:12.31%
controls:3.73%
cases:16.15%
controls:8.30%
58
245
246
2787
43
117
261
2915
17
16
287
3016
—
16
20
283
3001
32
109
228
2817
26
182
135
2012
Gas panel - Arterial blood
24336-0 [3019060]
2.4e+00
2.6e+00
—
—
—
1.9e+00
1.3e+00
cases:9.87%
controls:1.02%
cases:6.58%
controls:0.49%
—
—
—
—
—
—
cases:3.46%
controls:0.55%
cases:8.07%
controls:2.28%
30
31
274
3001
20
15
284
3017
—
—
—
9
16
251
2910
13
50
148
2144
Oxygen saturation in Arterial blood
2708-6 [3016502]
2.1e+00
2.2e+00
2.3e+00
—
—
1.4e+00
8.1e-01
cases:11.18%
controls:1.45%
cases:6.91%
controls:0.82%
cases:1.97%
controls:0.20%
—
—
—
—
cases:4.62%
controls:1.13%
cases:7.45%
controls:3.46%
34
44
270
2988
21
25
283
3007
6
6
298
3026
—
—
12
33
248
2893
12
76
149
2118
pH of Arterial blood
2744-1 [3019977]
2.0e+00
2.1e+00
2.5e+00
—
—
1.5e+00
7.5e-01
cases:11.51%
controls:1.78%
cases:7.89%
controls:1.06%
cases:1.97%
controls:0.16%
—
—
—
—
cases:5.00%
controls:1.13%
cases:8.07%
controls:3.97%
35
54
269
2978
24
32
280
3000
6
5
298
3027
—
—
13
33
247
2893
13
87
148
2107
carbamazepine; oral, rectal
N03AF01 [21604417]
1.7e+00
2.1e+00
—
—
2.1e+00
1.9e+00
2.4e+00
cases:5.59%
controls:1.12%
cases:4.61%
controls:0.59%
—
—
—
—
cases:1.67%
controls:0.20%
cases:3.46%
controls:0.55%
cases:7.45%
controls:0.73%
17
34
287
2998
14
18
290
3014
—
—
5
6
294
3015
9
16
251
2910
12
16
149
2178
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2.0e+00
2.1e+00
2.5e+00
—
—
1.4e+00
7.4e-01
cases:11.51%
controls:1.75%
cases:7.89%
controls:1.09%
cases:1.97%
controls:0.16%
—
—
—
—
cases:4.62%
controls:1.13%
cases:8.07%
controls:4.01%
35
53
269
2979
24
33
280
2999
6
5
298
3027
—
—
12
33
248
2893
13
88
148
2106
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2.0e+00
2.1e+00
2.5e+00
—
—
1.4e+00
7.4e-01
cases:11.51%
controls:1.75%
cases:7.89%
controls:1.09%
cases:1.97%
controls:0.16%
—
—
—
—
cases:4.62%
controls:1.13%
cases:8.07%
controls:4.01%
35
53
269
2979
24
33
280
2999
6
5
298
3027
—
—
12
33
248
2893
13
88
148
2106
rivastigmine; oral, transdermal
N06DA03 [21604796]
1.9e+00
2.0e+00
1.4e+00
—
2.2e+00
1.9e+00
3.5e-01
cases:5.92%
controls:0.96%
cases:5.59%
controls:0.82%
cases:1.64%
controls:0.40%
—
—
cases:3.01%
controls:0.33%
cases:6.54%
controls:1.03%
cases:3.73%
controls:2.64%
18
29
286
3003
17
25
287
3007
5
12
299
3020
—
9
10
290
3011
17
30
243
2896
6
58
155
2136
Parkinson disease
G20 [45538098]
1.6e+00
1.9e+00
2.3e+00
—
—
2.1e+00
1.2e+00
cases:4.61%
controls:0.92%
cases:3.95%
controls:0.59%
cases:2.30%
controls:0.23%
—
—
—
—
cases:4.62%
controls:0.62%
cases:3.73%
controls:1.14%
14
28
290
3004
12
18
292
3014
7
7
297
3025
—
—
12
18
248
2908
6
25
155
2169
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
1.1e+00
1.7e+00
2.3e+00
—
1.7e+00
1.2e+00
3.9e-01
cases:24.67%
controls:9.80%
cases:24.01%
controls:5.41%
cases:9.54%
controls:1.06%
—
—
cases:6.35%
controls:1.26%
cases:20.77%
controls:7.62%
cases:26.71%
controls:19.74%
75
297
229
2735
73
164
231
2868
29
32
275
3000
—
19
38
280
2983
54
223
206
2703
43
433
118
1761
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
1.1e+00
1.7e+00
2.3e+00
—
1.7e+00
1.2e+00
3.7e-01
cases:25.00%
controls:10.19%
cases:24.34%
controls:5.34%
cases:9.54%
controls:1.06%
—
—
cases:6.35%
controls:1.26%
cases:20.77%
controls:7.66%
cases:26.71%
controls:20.05%
76
309
228
2723
74
162
230
2870
29
32
275
3000
—
19
38
280
2983
54
224
206
2702
43
440
118
1754
quetiapine; oral
N05AH04 [21604544]
1.5e+00
1.6e+00
1.5e+00
—
1.6e+00
1.6e+00
1.6e+00
cases:8.22%
controls:2.04%
cases:7.57%
controls:1.55%
cases:1.64%
controls:0.36%
—
—
cases:2.68%
controls:0.53%
cases:8.46%
controls:1.91%
cases:16.15%
controls:3.78%
25
62
279
2970
23
47
281
2985
5
11
299
3021
—
8
16
291
3005
22
56
238
2870
26
83
135
2111
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
1.1e+00
1.7e+00
2.3e+00
—
1.7e+00
1.1e+00
4.0e-01
cases:25.00%
controls:10.42%
cases:24.01%
controls:5.47%
cases:9.54%
controls:1.09%
—
—
cases:6.69%
controls:1.26%
cases:20.77%
controls:7.76%
cases:27.33%
controls:20.15%
76
316
228
2716
73
166
231
2866
29
33
275
2999
—
20
38
279
2983
54
227
206
2699
44
442
117
1752
fentanyl; nasal, sublingual, transdermal
N02AB03 [21604272]
1.9e+00
2.9e+00
2.5e+00
—
—
2.4e+00
1.2e+00
cases:1.97%
controls:0.30%
cases:2.96%
controls:0.16%
cases:1.97%
controls:0.16%
—
—
—
—
cases:4.23%
controls:0.41%
cases:3.73%
controls:1.19%
6
9
298
3023
9
5
295
3027
6
5
298
3027
—
—
11
12
249
2914
6
26
155
2168
Outpatient Visit
OP [9202]
8.6e-01
7.4e-01
8.0e-01
4.2e+00
1.0e+00
3.6e-01
4.0e-01
cases:88.16%
controls:75.96%
cases:71.71%
controls:54.85%
cases:22.37%
controls:11.48%
cases:21.71%
controls:0.43%
cases:26.42%
controls:11.39%
cases:65.77%
controls:57.38%
cases:87.58%
controls:82.54%
268
2303
36
729
218
1663
86
1369
68
348
236
2684
66
13
238
3019
79
344
220
2677
171
1679
89
1247
141
1811
20
383
Osmolality of Urine
2695-5 [3026782]
1.0e+00
1.2e+00
2.0e+00
—
2.3e+00
1.0e+00
3.2e-01
cases:11.51%
controls:4.42%
cases:5.59%
controls:1.81%
cases:2.63%
controls:0.36%
—
—
cases:2.01%
controls:0.20%
cases:5.38%
controls:1.98%
cases:7.45%
controls:5.52%
35
134
269
2898
17
55
287
2977
8
11
296
3021
—
6
6
293
3015
14
58
246
2868
12
121
149
2073
Psychiatry
26 [38004469]
1.7e+00
2.4e+00
—
—
—
1.6e+00
1.8e+00
cases:11.51%
controls:2.31%
cases:7.89%
controls:0.76%
—
—
—
—
—
—
cases:5.38%
controls:1.13%
cases:11.80%
controls:2.19%
35
70
269
2962
24
23
280
3009
—
—
—
14
33
246
2893
19
48
142
2146
Assessment of need for aid
SPAT1229 [2001700330]
1.4e+00
2.8e+00
1.0e+50
—
—
1.6e+00
1.6e+00
cases:5.26%
controls:1.32%
cases:6.91%
controls:0.43%
cases:2.63%
controls:0.00%
—
—
—
—
cases:3.08%
controls:0.62%
cases:6.21%
controls:1.32%
16
40
288
2992
21
13
283
3019
8
0
296
3032
—
—
8
18
252
2908
10
29
151
2165
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
3.2e-01
1.0e+00
1.7e+00
2.7e+00
1.6e+00
5.2e-01
1.5e-01
cases:36.18%
controls:29.22%
cases:38.16%
controls:18.34%
cases:17.43%
controls:3.66%
cases:6.91%
controls:0.49%
cases:15.72%
controls:3.81%
cases:31.15%
controls:21.19%
cases:42.86%
controls:39.20%
110
886
194
2146
116
556
188
2476
53
111
251
2921
21
15
283
3017
47
115
252
2906
81
620
179
2306
69
860
92
1334
haloperidol; oral, parenteral
N05AD01 [21604516]
2.6e+00
2.6e+00
—
—
—
2.3e+00
—
cases:2.96%
controls:0.23%
cases:2.63%
controls:0.20%
—
—
—
—
—
—
cases:2.31%
controls:0.24%
—
—
9
7
295
3025
8
6
296
3026
—
—
—
6
7
254
2919
—
levodopa and decarboxylase inhibitor; oral
N04BA02 [21604465]
1.8e+00
1.6e+00
2.0e+00
—
—
2.1e+00
—
cases:5.92%
controls:1.06%
cases:4.93%
controls:0.99%
cases:2.96%
controls:0.43%
—
—
—
—
cases:6.15%
controls:0.82%
—
—
18
32
286
3000
15
30
289
3002
9
13
295
3019
—
—
16
24
244
2902
—
oxazepam; oral
N05BA04 [21604569]
9.1e-01
1.5e+00
1.9e+00
—
1.3e+00
1.5e+00
1.6e+00
cases:10.20%
controls:4.35%
cases:9.87%
controls:2.44%
cases:5.26%
controls:0.82%
—
—
cases:2.34%
controls:0.63%
cases:12.69%
controls:3.08%
cases:24.84%
controls:6.38%
31
132
273
2900
30
74
274
2958
16
25
288
3007
—
7
19
292
3002
33
90
227
2836
40
140
121
2054
Inpatient Visit
IP [9201]
7.5e-01
1.4e+00
2.2e+00
1.0e+50
2.1e+00
8.9e-01
4.5e-01
cases:13.16%
controls:6.70%
cases:11.18%
controls:3.13%
cases:3.62%
controls:0.40%
cases:4.93%
controls:0.00%
cases:3.01%
controls:0.36%
cases:8.08%
controls:3.49%
cases:13.66%
controls:9.16%
40
203
264
2829
34
95
270
2937
11
12
293
3020
15
0
289
3032
9
11
290
3010
21
102
239
2824
22
201
139
1993
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
1.8e+00
1.2e+00
2.5e+00
—
-1.0e+50
1.5e+00
1.3e+00
cases:5.59%
controls:0.99%
cases:2.96%
controls:0.89%
cases:2.30%
controls:0.20%
—
—
cases:0.00%
controls:0.30%
cases:3.46%
controls:0.79%
cases:6.21%
controls:1.69%
17
30
287
3002
9
27
295
3005
7
6
297
3026
—
0
9
299
3012
9
23
251
2903
10
37
151
2157
memantine; oral
N06DX01 [21604799]
1.6e+00
1.5e+00
1.4e+00
-1.0e+50
1.1e+00
1.7e+00
9.1e-01
cases:9.21%
controls:1.91%
cases:9.54%
controls:2.31%
cases:4.93%
controls:1.29%
cases:0.00%
controls:0.23%
cases:3.34%
controls:1.16%
cases:13.46%
controls:2.84%
cases:13.04%
controls:5.70%
28
58
276
2974
29
70
275
2962
15
39
289
2993
0
7
304
3025
10
35
289
2986
35
83
225
2843
21
125
140
2069
Palliative care
Z51.5 [45547323]
—
3.0e+00
—
1.0e+50
—
2.6e+00
1.5e+00
—
—
cases:3.29%
controls:0.16%
—
—
cases:1.97%
controls:0.00%
—
—
cases:3.08%
controls:0.24%
cases:6.83%
controls:1.69%
—
10
5
294
3027
—
6
0
298
3032
—
8
7
252
2919
11
37
150
2157
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
2.1e+00
2.4e+00
2.5e+00
—
—
1.4e+00
8.6e-01
cases:10.53%
controls:1.39%
cases:7.24%
controls:0.69%
cases:1.97%
controls:0.16%
—
—
—
—
cases:3.85%
controls:1.03%
cases:7.45%
controls:3.28%
32
42
272
2990
22
21
282
3011
6
5
298
3027
—
—
10
30
250
2896
12
72
149
2122
macrogol; oral
A06AD15 [21600575]
1.5e+00
1.8e+00
—
—
—
2.2e+00
1.5e+00
cases:5.59%
controls:1.32%
cases:3.62%
controls:0.59%
—
—
—
—
—
—
cases:6.15%
controls:0.72%
cases:11.80%
controls:2.92%
17
40
287
2992
11
18
293
3014
—
—
—
16
21
244
2905
19
64
142
2130
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
7.5e-01
1.4e+00
2.1e+00
—
1.6e+00
1.0e+00
4.1e-01
cases:30.26%
controls:16.95%
cases:25.99%
controls:8.08%
cases:11.18%
controls:1.45%
—
—
cases:7.69%
controls:1.69%
cases:23.85%
controls:9.88%
cases:32.30%
controls:24.07%
92
514
212
2518
79
245
225
2787
34
44
270
2988
—
23
51
276
2970
62
289
198
2637
52
528
109
1666
Bacteria identified in Blood by Culture
600-7 [3023368]
1.3e+00
1.8e+00
2.3e+00
—
—
1.4e+00
7.3e-01
cases:18.09%
controls:5.67%
cases:14.47%
controls:2.64%
cases:4.28%
controls:0.43%
—
—
—
—
cases:10.38%
controls:2.73%
cases:18.01%
controls:9.57%
55
172
249
2860
44
80
260
2952
13
13
291
3019
—
—
27
80
233
2846
29
210
132
1984
potassium chloride; oral
A12BA01 [21600877]
1.1e+00
1.3e+00
1.7e+00
—
1.6e+00
1.1e+00
6.8e-01
cases:9.54%
controls:3.27%
cases:7.89%
controls:2.24%
cases:3.62%
controls:0.66%
—
—
cases:3.34%
controls:0.70%
cases:6.54%
controls:2.29%
cases:9.94%
controls:5.29%
29
99
275
2933
24
68
280
2964
11
20
293
3012
—
10
21
289
3000
17
67
243
2859
16
116
145
2078
Taking care of patient’s/customer’s hygiene
SPAT1137 [2001700238]
7.3e-01
1.5e+00
1.6e+00
—
2.2e+00
1.5e+00
6.4e-01
cases:1.97%
controls:0.96%
cases:4.61%
controls:1.02%
cases:2.63%
controls:0.53%
—
—
cases:3.68%
controls:0.43%
cases:4.62%
controls:1.06%
cases:4.97%
controls:2.69%
6
29
298
3003
14
31
290
3001
8
16
296
3016
—
11
13
288
3008
12
31
248
2895
8
59
153
2135
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
4.3e-01
7.8e-01
1.5e+00
2.7e+00
1.3e+00
3.7e-01
1.7e-01
cases:36.84%
controls:27.54%
cases:38.16%
controls:22.10%
cases:19.41%
controls:4.95%
cases:6.91%
controls:0.49%
cases:16.05%
controls:5.03%
cases:32.31%
controls:24.74%
cases:40.37%
controls:36.28%
112
835
192
2197
116
670
188
2362
59
150
245
2882
21
15
283
3017
48
152
251
2869
84
724
176
2202
65
796
96
1398
Unspecified dementia
F03 [45566772]
1.5e+00
2.0e+00
—
—
—
1.6e+00
1.5e+00
cases:4.28%
controls:0.96%
cases:3.29%
controls:0.46%
—
—
—
—
—
—
cases:3.08%
controls:0.62%
cases:9.32%
controls:2.23%
13
29
291
3003
10
14
294
3018
—
—
—
8
18
252
2908
15
49
146
2145
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
1.2e+00
2.2e+00
—
—
—
1.9e+00
1.3e+00
cases:6.58%
controls:1.98%
cases:4.93%
controls:0.59%
—
—
—
—
—
—
cases:4.62%
controls:0.72%
cases:9.94%
controls:2.96%
20
60
284
2972
15
18
289
3014
—
—
—
12
21
248
2905
16
65
145
2129
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
4.4e-01
7.0e-01
1.4e+00
2.8e+00
1.2e+00
2.2e-01
7.5e-02
cases:31.91%
controls:23.22%
cases:33.22%
controls:19.79%
cases:17.43%
controls:4.88%
cases:5.59%
controls:0.36%
cases:14.05%
controls:4.60%
cases:26.15%
controls:22.18%
cases:34.78%
controls:33.09%
97
704
207
2328
101
600
203
2432
53
148
251
2884
17
11
287
3021
42
139
257
2882
68
649
192
2277
56
726
105
1468
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
6.3e-01
1.4e+00
2.1e+00
—
1.5e+00
9.1e-01
2.7e-01
cases:28.29%
controls:17.41%
cases:25.66%
controls:8.21%
cases:10.20%
controls:1.32%
—
—
cases:7.02%
controls:1.62%
cases:21.54%
controls:9.91%
cases:29.19%
controls:23.93%
86
528
218
2504
78
249
226
2783
31
40
273
2992
—
21
49
278
2972
56
290
204
2636
47
525
114
1669
Cerebral infarction, unspecified
I63.9 [45596216]
1.3e+00
2.2e+00
—
—
—
1.9e+00
1.2e+00
cases:9.21%
controls:2.67%
cases:6.25%
controls:0.76%
—
—
—
—
—
—
cases:5.38%
controls:0.85%
cases:9.32%
controls:3.05%
28
81
276
2951
19
23
285
3009
—
—
—
14
25
246
2901
15
67
146
2127
trimethoprim; oral, parenteral
J01EA01 [21602931]
8.4e-01
1.2e+00
1.9e+00
—
1.6e+00
1.3e+00
1.1e+00
cases:14.80%
controls:6.96%
cases:10.20%
controls:3.23%
cases:3.29%
controls:0.49%
—
—
cases:2.68%
controls:0.56%
cases:11.15%
controls:3.28%
cases:21.74%
controls:8.52%
45
211
259
2821
31
98
273
2934
10
15
294
3017
—
8
17
291
3004
29
96
231
2830
35
187
126
2007
furosemide; oral, parenteral
C03CA01 [21601518]
9.3e-01
1.3e+00
1.3e+00
—
9.0e-01
1.0e+00
9.0e-01
cases:27.30%
controls:12.96%
cases:32.24%
controls:11.41%
cases:12.50%
controls:3.69%
—
—
cases:9.36%
controls:4.04%
cases:29.23%
controls:12.75%
cases:38.51%
controls:20.37%
83
393
221
2639
98
346
206
2686
38
112
266
2920
—
28
122
271
2899
76
373
184
2553
62
447
99
1747
Provision of support and information to patient’s family members
SPAT1245 [2001700346]
2.2e+00
2.3e+00
—
—
—
1.8e+00
6.2e-01
cases:5.59%
controls:0.66%
cases:3.95%
controls:0.40%
—
—
—
—
—
—
cases:3.08%
controls:0.51%
cases:3.11%
controls:1.69%
17
20
287
3012
12
12
292
3020
—
—
—
8
15
252
2911
5
37
156
2157
Sequelae of cerebral infarction
I69.3 [45533476]
1.6e+00
1.8e+00
—
1.0e+50
—
1.7e+00
1.3e+00
cases:7.89%
controls:1.75%
cases:5.92%
controls:1.02%
—
—
cases:2.63%
controls:0.00%
—
—
cases:6.54%
controls:1.26%
cases:11.80%
controls:3.65%
24
53
280
2979
18
31
286
3001
—
8
0
296
3032
—
17
37
243
2889
19
80
142
2114
Treatment of a patient needing special arrangements
WYA30 [2001310874]
1.6e+00
2.4e+00
—
—
—
—
2.2e+00
cases:3.29%
controls:0.66%
cases:2.96%
controls:0.26%
—
—
—
—
—
—
—
—
cases:8.70%
controls:1.00%
10
20
294
3012
9
8
295
3024
—
—
—
—
14
22
147
2172
Acute tubulo-interstitial nephritis
N10 [45543856]
1.2e+00
1.9e+00
—
—
—
2.0e+00
1.2e+00
cases:7.89%
controls:2.51%
cases:5.59%
controls:0.86%
—
—
—
—
—
—
cases:5.38%
controls:0.79%
cases:12.42%
controls:4.19%
24
76
280
2956
17
26
287
3006
—
—
—
14
23
246
2903
20
92
141
2102
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
1.1e+00
1.3e+00
1.7e+00
—
1.5e+00
1.3e+00
9.0e-01
cases:7.57%
controls:2.77%
cases:5.26%
controls:1.52%
cases:3.62%
controls:0.66%
—
—
cases:2.34%
controls:0.53%
cases:7.69%
controls:2.29%
cases:13.04%
controls:5.74%
23
84
281
2948
16
46
288
2986
11
20
293
3012
—
7
16
292
3005
20
67
240
2859
21
126
140
2068
Pharmacy visit
OMOP4822462 [581458]
1.4e+00
1.9e+00
1.1e+00
4.6e-01
1.0e+00
2.2e+00
1.3e-01
cases:99.01%
controls:96.17%
cases:98.36%
controls:90.24%
cases:80.26%
controls:57.52%
cases:5.26%
controls:3.40%
cases:79.26%
controls:57.73%
cases:98.85%
controls:90.53%
cases:97.52%
controls:97.17%
301
2916
3
116
299
2736
5
296
244
1744
60
1288
16
103
288
2929
237
1744
62
1277
257
2649
3
277
157
2132
4
62
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
1.8e+00
2.7e+00
—
—
—
1.7e+00
1.6e+00
cases:5.59%
controls:0.92%
cases:4.28%
controls:0.30%
—
—
—
—
—
—
cases:2.31%
controls:0.44%
cases:9.32%
controls:2.05%
17
28
287
3004
13
9
291
3023
—
—
—
6
13
254
2913
15
45
146
2149
Outpatient Hospital
22 [8756]
9.5e-01
1.3e+00
1.3e+00
1.0e+50
1.4e+00
1.1e+00
4.8e-01
cases:52.30%
controls:29.85%
cases:25.66%
controls:8.77%
cases:4.28%
controls:1.15%
cases:2.96%
controls:0.00%
cases:4.35%
controls:1.09%
cases:19.62%
controls:7.66%
cases:34.16%
controls:24.29%
159
905
145
2127
78
266
226
2766
13
35
291
2997
9
0
295
3032
13
33
286
2988
51
224
209
2702
55
533
106
1661
Assessment of need for services (elderly/care support)
SPAT1217 [2001700318]
1.8e+00
2.5e+00
—
—
—
1.7e+00
3.3e-02
cases:11.18%
controls:1.98%
cases:10.53%
controls:0.99%
—
—
—
—
—
—
cases:5.38%
controls:0.99%
cases:3.11%
controls:3.01%
34
60
270
2972
32
30
272
3002
—
—
—
14
29
246
2897
5
66
156
2128
Bacteria [Presence] in Urine
87829-8 [36304419]
9.4e-01
1.3e+00
2.2e+00
—
1.5e+00
8.5e-01
1.8e-01
cases:12.83%
controls:5.44%
cases:9.54%
controls:2.80%
cases:4.28%
controls:0.49%
—
—
cases:3.01%
controls:0.66%
cases:7.31%
controls:3.25%
cases:9.94%
controls:8.43%
39
165
265
2867
29
85
275
2947
13
15
291
3017
—
9
20
290
3001
19
95
241
2831
16
185
145
2009
Primary degenerative dementia of the Alzheimer's type, senile onset without additional symptoms
F00.10*G30.1 [2000501573]
1.8e+00
2.0e+00
—
1.0e+50
—
2.1e+00
7.6e-01
cases:4.28%
controls:0.73%
cases:3.29%
controls:0.46%
—
—
cases:1.64%
controls:0.00%
—
—
cases:3.85%
controls:0.48%
cases:3.73%
controls:1.78%
13
22
291
3010
10
14
294
3018
—
5
0
299
3032
—
10
14
250
2912
6
39
155
2155
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.8e-01
6.6e-01
1.3e+00
2.7e+00
1.3e+00
2.9e-01
6.0e-02
cases:32.57%
controls:24.80%
cases:34.87%
controls:21.67%
cases:16.12%
controls:4.95%
cases:5.92%
controls:0.43%
cases:17.06%
controls:5.49%
cases:29.23%
controls:23.62%
cases:37.27%
controls:35.87%
99
752
205
2280
106
657
198
2375
49
150
255
2882
18
13
286
3019
51
166
248
2855
76
691
184
2235
60
787
101
1407
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
1.1e+00
1.2e+00
2.3e+00
—
1.6e+00
1.2e+00
1.4e-01
cases:12.17%
controls:4.25%
cases:6.58%
controls:1.98%
cases:2.63%
controls:0.26%
—
—
cases:2.01%
controls:0.40%
cases:6.92%
controls:2.22%
cases:7.45%
controls:6.56%
37
129
267
2903
20
60
284
2972
8
8
296
3024
—
6
12
293
3009
18
65
242
2861
12
144
149
2050
Anion gap in Blood by calculation
41276-7 [3039000]
2.9e+00
2.9e+00
—
—
—
—
—
cases:5.92%
controls:0.33%
cases:2.96%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
18
10
286
3022
9
5
295
3027
—
—
—
—
—
Chloride [Moles/volume] in Blood
2069-3 [3018572]
2.9e+00
2.9e+00
—
—
—
—
—
cases:5.92%
controls:0.33%
cases:2.96%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
18
10
286
3022
9
5
295
3027
—
—
—
—
—
Norovirus RNA [Presence] in Stool by NAA with probe detection
7974-9 [3008909]
2.3e+00
—
—
—
—
2.0e+00
1.5e+00
cases:2.30%
controls:0.23%
—
—
—
—
—
—
—
—
cases:2.31%
controls:0.31%
cases:5.59%
controls:1.32%
7
7
297
3025
—
—
—
—
6
9
254
2917
9
29
152
2165
Essential (primary) hypertension
I10 [45591453]
4.3e-01
8.5e-01
1.1e+00
3.9e+00
9.0e-01
4.6e-01
-1.2e-01
cases:33.88%
controls:25.07%
cases:25.00%
controls:12.47%
cases:6.25%
controls:2.28%
cases:7.57%
controls:0.16%
cases:5.69%
controls:2.38%
cases:19.23%
controls:13.02%
cases:31.06%
controls:33.68%
103
760
201
2272
76
378
228
2654
19
69
285
2963
23
5
281
3027
17
72
282
2949
50
381
210
2545
50
739
111
1455
Lactate [Moles/volume] in Blood
32693-4 [3047181]
2.7e+00
3.0e+00
—
—
—
—
1.5e+00
cases:6.25%
controls:0.46%
cases:3.95%
controls:0.20%
—
—
—
—
—
—
—
—
cases:3.73%
controls:0.82%
19
14
285
3018
12
6
292
3026
—
—
—
—
6
18
155
2176
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
7.5e-01
1.3e+00
1.6e+00
—
1.2e+00
8.1e-01
1.3e-02
cases:19.74%
controls:10.39%
cases:18.42%
controls:5.67%
cases:5.59%
controls:1.15%
—
—
cases:4.68%
controls:1.49%
cases:13.46%
controls:6.46%
cases:15.53%
controls:15.36%
60
315
244
2717
56
172
248
2860
17
35
287
2997
—
14
45
285
2976
35
189
225
2737
25
337
136
1857
gabapentin; oral
N02BF01 [955005]
1.3e+00
1.4e+00
1.8e+00
—
1.4e+00
1.1e+00
7.5e-01
cases:10.53%
controls:3.20%
cases:5.92%
controls:1.48%
cases:2.63%
controls:0.43%
—
—
cases:2.34%
controls:0.60%
cases:6.15%
controls:2.22%
cases:8.07%
controls:3.97%
32
97
272
2935
18
45
286
2987
8
13
296
3019
—
7
18
292
3003
16
65
244
2861
13
87
148
2107
Base excess in Arterial blood by calculation
1925-7 [3003396]
2.0e+00
2.0e+00
—
—
—
1.5e+00
7.5e-01
cases:11.84%
controls:1.78%
cases:7.57%
controls:1.06%
—
—
—
—
—
—
cases:5.00%
controls:1.20%
cases:8.07%
controls:3.97%
36
54
268
2978
23
32
281
3000
—
—
—
13
35
247
2891
13
87
148
2107
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
9.2e-01
1.1e+00
1.9e+00
—
1.6e+00
7.4e-01
1.1e-01
cases:14.80%
controls:6.50%
cases:9.87%
controls:3.46%
cases:4.28%
controls:0.69%
—
—
cases:3.68%
controls:0.76%
cases:8.85%
controls:4.41%
cases:12.42%
controls:11.30%
45
197
259
2835
30
105
274
2927
13
21
291
3011
—
11
23
288
2998
23
129
237
2797
20
248
141
1946
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.4e-01
6.5e-01
1.3e+00
2.4e+00
1.2e+00
2.5e-01
-2.5e-02
cases:41.45%
controls:35.82%
cases:42.76%
controls:28.00%
cases:19.08%
controls:6.04%
cases:6.91%
controls:0.69%
cases:17.73%
controls:6.32%
cases:36.92%
controls:31.37%
cases:45.96%
controls:46.58%
126
1086
178
1946
130
849
174
2183
58
183
246
2849
21
21
283
3011
53
191
246
2830
96
918
164
2008
74
1022
87
1172
Atherosclerosis of arteries of extremities
I70.2 [45538421]
1.0e+00
1.3e+00
1.1e+00
—
1.8e+00
1.3e+00
6.0e-01
cases:7.24%
controls:2.77%
cases:5.92%
controls:1.72%
cases:1.64%
controls:0.56%
—
—
cases:2.34%
controls:0.40%
cases:5.77%
controls:1.64%
cases:6.83%
controls:3.87%
22
84
282
2948
18
52
286
2980
5
17
299
3015
—
7
12
292
3009
15
48
245
2878
11
85
150
2109
CBC panel - Blood by Automated count
58410-2 [40761511]
2.7e-01
7.0e-01
1.4e+00
2.2e+00
1.1e+00
3.0e-01
-5.2e-02
cases:39.14%
controls:33.01%
cases:36.18%
controls:22.00%
cases:15.46%
controls:4.29%
cases:3.62%
controls:0.43%
cases:13.04%
controls:4.73%
cases:30.00%
controls:24.13%
cases:38.51%
controls:39.74%
119
1001
185
2031
110
667
194
2365
47
130
257
2902
11
13
293
3019
39
143
260
2878
78
706
182
2220
62
872
99
1322
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.3e-01
6.4e-01
1.3e+00
2.4e+00
1.1e+00
2.3e-01
-3.0e-02
cases:41.45%
controls:35.92%
cases:42.76%
controls:28.33%
cases:18.42%
controls:6.04%
cases:6.91%
controls:0.69%
cases:17.39%
controls:6.52%
cases:36.92%
controls:31.75%
cases:45.96%
controls:46.72%
126
1089
178
1943
130
859
174
2173
56
183
248
2849
21
21
283
3011
52
197
247
2824
96
929
164
1997
74
1025
87
1169
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
2.4e+00
—
—
—
—
—
2.9e+00
cases:4.28%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
cases:5.59%
controls:0.32%
13
12
291
3020
—
—
—
—
—
9
7
152
2187
Alzheimer disease, unspecified
G30.9 [45591165]
1.9e+00
1.9e+00
—
—
—
2.1e+00
1.3e+00
cases:2.63%
controls:0.40%
cases:1.97%
controls:0.30%
—
—
—
—
—
—
cases:3.85%
controls:0.48%
cases:6.83%
controls:1.96%
8
12
296
3020
6
9
298
3023
—
—
—
10
14
250
2912
11
43
150
2151
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.7e-01
5.2e-01
1.2e+00
2.5e+00
1.1e+00
1.6e-01
-1.2e-01
cases:42.11%
controls:37.93%
cases:44.08%
controls:31.93%
cases:21.71%
controls:7.55%
cases:7.89%
controls:0.69%
cases:19.73%
controls:7.71%
cases:39.62%
controls:35.95%
cases:46.58%
controls:49.64%
128
1150
176
1882
134
968
170
2064
66
229
238
2803
24
21
280
3011
59
233
240
2788
103
1052
157
1874
75
1089
86
1105
Platelets [#/volume] in Blood
26515-7 [3007461]
1.8e-01
5.3e-01
1.2e+00
2.5e+00
1.1e+00
1.6e-01
-1.2e-01
cases:42.11%
controls:37.83%
cases:44.08%
controls:31.73%
cases:21.71%
controls:7.52%
cases:7.89%
controls:0.69%
cases:19.40%
controls:7.71%
cases:39.62%
controls:35.85%
cases:46.58%
controls:49.54%
128
1147
176
1885
134
962
170
2070
66
228
238
2804
24
21
280
3011
58
233
241
2788
103
1049
157
1877
75
1087
86
1107
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.7e-01
5.2e-01
1.2e+00
2.5e+00
1.1e+00
1.5e-01
-1.2e-01
cases:42.11%
controls:37.96%
cases:44.08%
controls:31.96%
cases:21.71%
controls:7.55%
cases:7.89%
controls:0.69%
cases:19.40%
controls:7.68%
cases:39.62%
controls:35.99%
cases:46.58%
controls:49.64%
128
1151
176
1881
134
969
170
2063
66
229
238
2803
24
21
280
3011
58
232
241
2789
103
1053
157
1873
75
1089
86
1105
MCH [Entitic mass]
28539-5 [3035941]
1.7e-01
5.2e-01
1.2e+00
2.5e+00
1.1e+00
1.6e-01
-1.2e-01
cases:42.11%
controls:37.93%
cases:44.08%
controls:31.86%
cases:21.71%
controls:7.55%
cases:7.89%
controls:0.69%
cases:19.40%
controls:7.71%
cases:39.62%
controls:35.95%
cases:46.58%
controls:49.64%
128
1150
176
1882
134
966
170
2066
66
229
238
2803
24
21
280
3011
58
233
241
2788
103
1052
157
1874
75
1089
86
1105
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.7e-01
5.2e-01
1.2e+00
2.5e+00
1.1e+00
1.6e-01
-1.2e-01
cases:42.11%
controls:37.93%
cases:44.08%
controls:31.89%
cases:21.71%
controls:7.55%
cases:7.89%
controls:0.69%
cases:19.40%
controls:7.71%
cases:39.62%
controls:35.95%
cases:46.58%
controls:49.64%
128
1150
176
1882
134
967
170
2065
66
229
238
2803
24
21
280
3011
58
233
241
2788
103
1052
157
1874
75
1089
86
1105
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.7e-01
5.2e-01
1.2e+00
2.5e+00
1.1e+00
1.6e-01
-1.2e-01
cases:42.11%
controls:37.93%
cases:44.08%
controls:31.89%
cases:21.71%
controls:7.55%
cases:7.89%
controls:0.69%
cases:19.40%
controls:7.71%
cases:39.62%
controls:35.92%
cases:46.58%
controls:49.64%
128
1150
176
1882
134
967
170
2065
66
229
238
2803
24
21
280
3011
58
233
241
2788
103
1051
157
1875
75
1089
86
1105
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.7e-01
5.2e-01
1.2e+00
2.5e+00
1.0e+00
1.2e-01
-1.2e-01
cases:42.11%
controls:37.93%
cases:44.08%
controls:31.93%
cases:21.71%
controls:7.59%
cases:7.89%
controls:0.69%
cases:19.06%
controls:7.71%
cases:38.85%
controls:35.95%
cases:46.58%
controls:49.68%
128
1150
176
1882
134
968
170
2064
66
230
238
2802
24
21
280
3011
57
233
242
2788
101
1052
159
1874
75
1090
86
1104
escitalopram; oral
N06AB10 [21604718]
9.6e-01
1.3e+00
—
—
1.7e+00
1.5e+00
1.5e+00
cases:5.59%
controls:2.21%
cases:4.61%
controls:1.35%
—
—
—
—
cases:1.67%
controls:0.30%
cases:6.54%
controls:1.50%
cases:11.80%
controls:2.92%
17
67
287
2965
14
41
290
2991
—
—
5
9
294
3012
17
44
243
2882
19
64
142
2130
Leukocytes [#/volume] in Urine
30405-5 [3018095]
8.4e-01
1.0e+00
1.7e+00
—
1.7e+00
7.2e-01
2.3e-03
cases:15.13%
controls:7.12%
cases:10.20%
controls:3.83%
cases:4.28%
controls:0.82%
—
—
cases:4.35%
controls:0.86%
cases:9.62%
controls:4.92%
cases:12.42%
controls:12.40%
46
216
258
2816
31
116
273
2916
13
25
291
3007
—
13
26
286
2995
25
144
235
2782
20
272
141
1922
donepezil; oral
N06DA02 [21604795]
1.3e+00
1.1e+00
1.3e+00
—
1.6e+00
1.2e+00
2.1e-01
cases:7.24%
controls:2.14%
cases:5.92%
controls:2.04%
cases:2.63%
controls:0.73%
—
—
cases:3.34%
controls:0.70%
cases:7.69%
controls:2.43%
cases:6.21%
controls:5.10%
22
65
282
2967
18
62
286
2970
8
22
296
3010
—
10
21
289
3000
20
71
240
2855
10
112
151
2082
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
2.1e+00
1.6e+00
—
—
—
1.5e+00
-2.8e-02
cases:7.89%
controls:1.09%
cases:3.29%
controls:0.69%
—
—
—
—
—
—
cases:5.00%
controls:1.16%
cases:3.11%
controls:3.19%
24
33
280
2999
10
21
294
3011
—
—
—
13
34
247
2892
5
70
156
2124
Administration of medicine
SPAT1254 [2001700355]
9.5e-01
1.4e+00
1.3e+00
—
1.5e+00
1.3e+00
8.2e-01
cases:5.59%
controls:2.24%
cases:6.25%
controls:1.65%
cases:2.63%
controls:0.73%
—
—
cases:3.34%
controls:0.76%
cases:5.38%
controls:1.57%
cases:9.94%
controls:4.65%
17
68
287
2964
19
50
285
2982
8
22
296
3010
—
10
23
289
2998
14
46
246
2880
16
102
145
2092
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.1e-01
5.2e-01
1.1e+00
2.3e+00
1.1e+00
2.2e-01
-9.3e-02
cases:42.11%
controls:36.97%
cases:43.09%
controls:30.94%
cases:19.41%
controls:7.16%
cases:6.91%
controls:0.73%
cases:19.73%
controls:7.48%
cases:39.62%
controls:34.59%
cases:45.96%
controls:48.27%
128
1121
176
1911
131
938
173
2094
59
217
245
2815
21
22
283
3010
59
226
240
2795
103
1012
157
1914
74
1059
87
1135
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
7.0e-01
1.4e+00
2.1e+00
—
1.6e+00
8.5e-01
4.9e-01
cases:16.45%
controls:8.94%
cases:16.45%
controls:4.62%
cases:5.26%
controls:0.66%
—
—
cases:2.68%
controls:0.56%
cases:11.92%
controls:5.47%
cases:21.12%
controls:14.08%
50
271
254
2761
50
140
254
2892
16
20
288
3012
—
8
17
291
3004
31
160
229
2766
34
309
127
1885
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
8.1e-01
1.1e+00
1.6e+00
—
1.5e+00
7.1e-01
2.3e-02
cases:15.79%
controls:7.72%
cases:10.86%
controls:3.96%
cases:3.95%
controls:0.79%
—
—
cases:3.34%
controls:0.76%
cases:9.23%
controls:4.75%
cases:12.42%
controls:12.17%
48
234
256
2798
33
120
271
2912
12
24
292
3008
—
10
23
289
2998
24
139
236
2787
20
267
141
1927
Internal Medicine
11 [38004456]
1.0e+00
1.1e+00
8.3e-01
—
1.3e+00
9.5e-01
6.1e-01
cases:51.32%
controls:27.64%
cases:29.93%
controls:12.34%
cases:4.93%
controls:2.21%
—
—
cases:6.69%
controls:1.89%
cases:25.77%
controls:11.86%
cases:44.10%
controls:29.95%
156
838
148
2194
91
374
213
2658
15
67
289
2965
—
20
57
279
2964
67
347
193
2579
71
657
90
1537
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
2.4e+00
2.6e+00
—
—
—
1.5e+00
1.1e+00
cases:9.87%
controls:1.02%
cases:6.91%
controls:0.56%
—
—
—
—
—
—
cases:3.08%
controls:0.72%
cases:7.45%
controls:2.51%
30
31
274
3001
21
17
283
3015
—
—
—
8
21
252
2905
12
55
149
2139
Monitored bed care
WX892 [2001310850]
1.8e+00
3.1e+00
—
—
—
1.6e+00
1.1e+00
cases:4.61%
controls:0.79%
cases:3.62%
controls:0.16%
—
—
—
—
—
—
cases:2.31%
controls:0.48%
cases:3.11%
controls:1.05%
14
24
290
3008
11
5
293
3027
—
—
—
6
14
254
2912
5
23
156
2171
Malaise and fatigue
R53 [45553741]
1.1e+00
1.5e+00
—
—
—
1.5e+00
8.8e-01
cases:8.88%
controls:3.23%
cases:6.58%
controls:1.58%
—
—
—
—
—
—
cases:7.31%
controls:1.78%
cases:14.29%
controls:6.47%
27
98
277
2934
20
48
284
2984
—
—
—
19
52
241
2874
23
142
138
2052
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
2.5e+00
2.4e+00
—
—
—
—
9.3e-01
cases:7.57%
controls:0.69%
cases:4.61%
controls:0.43%
—
—
—
—
—
—
—
—
cases:3.73%
controls:1.50%
23
21
281
3011
14
13
290
3019
—
—
—
—
6
33
155
2161
duloxetine; oral
N06AX21 [21604749]
1.5e+00
1.2e+00
—
—
—
1.6e+00
1.7e+00
cases:4.28%
controls:0.96%
cases:1.97%
controls:0.63%
—
—
—
—
—
—
cases:3.08%
controls:0.62%
cases:6.21%
controls:1.19%
13
29
291
3003
6
19
298
3013
—
—
—
8
18
252
2908
10
26
151
2168
Stroke/cerebrovascular accident
K90 [2002000617]
2.2e+00
2.6e+00
—
—
—
—
—
cases:3.62%
controls:0.40%
cases:2.63%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
11
12
293
3020
8
6
296
3026
—
—
—
—
—
azathioprine; oral, parenteral
L04AX01 [21603927]
2.5e+00
2.3e+00
—
—
—
—
—
cases:3.95%
controls:0.33%
cases:2.63%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
12
10
292
3022
8
8
296
3024
—
—
—
—
—
Rehabilitation Hospital
283X00000X [38004285]
1.9e+00
—
—
—
—
—
2.9e+00
cases:2.63%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
cases:5.59%
controls:0.32%
8
12
296
3020
—
—
—
—
—
9
7
152
2187
Voluntary or Charitable Agency
251V00000X [38004202]
2.6e+00
2.2e+00
—
—
—
—
8.7e-01
cases:3.95%
controls:0.30%
cases:1.97%
controls:0.23%
—
—
—
—
—
—
—
—
cases:3.11%
controls:1.32%
12
9
292
3023
6
7
298
3025
—
—
—
—
5
29
156
2165
Nursing episode
950 [44777714]
1.1e+00
1.1e+00
1.4e+00
—
1.3e+00
1.2e+00
6.6e-01
cases:8.55%
controls:3.10%
cases:6.58%
controls:2.21%
cases:3.95%
controls:1.02%
—
—
cases:3.68%
controls:1.06%
cases:8.46%
controls:2.73%
cases:11.80%
controls:6.47%
26
94
278
2938
20
67
284
2965
12
31
292
3001
—
11
32
288
2989
22
80
238
2846
19
142
142
2052
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
9.2e-01
1.1e+00
1.6e+00
—
9.4e-01
1.6e+00
1.1e+00
cases:7.24%
controls:3.00%
cases:4.93%
controls:1.68%
cases:2.30%
controls:0.49%
—
—
cases:1.67%
controls:0.66%
cases:7.69%
controls:1.64%
cases:12.42%
controls:4.38%
22
91
282
2941
15
51
289
2981
7
15
297
3017
—
5
20
294
3001
20
48
240
2878
20
96
141
2098
Methemoglobin/Hemoglobin.total in Blood
2614-6 [3007930]
2.4e+00
2.2e+00
—
—
—
—
5.5e-01
cases:5.92%
controls:0.56%
cases:3.62%
controls:0.40%
—
—
—
—
—
—
—
—
cases:3.11%
controls:1.82%
18
17
286
3015
11
12
293
3020
—
—
—
—
5
40
156
2154
Alzheimer disease with late onset
G30.1 [45552521]
1.8e+00
1.6e+00
—
—
1.9e+00
1.3e+00
2.3e-01
cases:8.22%
controls:1.52%
cases:5.92%
controls:1.29%
—
—
—
—
cases:1.67%
controls:0.26%
cases:5.77%
controls:1.64%
cases:6.83%
controls:5.52%
25
46
279
2986
18
39
286
2993
—
—
5
8
294
3013
15
48
245
2878
11
121
150
2073
Complex partial epileptic seizure with secondary generalization
G40.22 [2000502141]
—
2.5e+00
—
—
—
—
2.1e+00
—
—
cases:2.30%
controls:0.20%
—
—
—
—
—
—
—
—
cases:3.73%
controls:0.46%
—
7
6
297
3026
—
—
—
—
6
10
155
2184
levetiracetam; oral, parenteral
N03AX14 [21604436]
2.2e+00
2.4e+00
—
—
—
2.0e+00
1.5e+00
cases:1.97%
controls:0.23%
cases:2.96%
controls:0.26%
—
—
—
—
—
—
cases:1.92%
controls:0.27%
cases:3.73%
controls:0.87%
6
7
298
3025
9
8
295
3024
—
—
—
5
8
255
2918
6
19
155
2175
Carboxyhemoglobin/Hemoglobin.total in Blood
20563-3 [3023081]
2.4e+00
2.2e+00
—
—
—
—
4.3e-01
cases:5.92%
controls:0.56%
cases:3.62%
controls:0.43%
—
—
—
—
—
—
—
—
cases:3.11%
controls:2.05%
18
17
286
3015
11
13
293
3019
—
—
—
—
5
45
156
2149
Case Management Agency
251B00000X [38004193]
3.3e-01
3.5e-01
7.2e-01
3.2e+00
6.7e-01
9.2e-03
-4.6e-02
cases:70.39%
controls:63.16%
cases:63.82%
controls:55.34%
cases:38.49%
controls:23.42%
cases:26.97%
controls:1.52%
cases:37.12%
controls:23.20%
cases:56.92%
controls:56.70%
cases:75.78%
controls:76.62%
214
1915
90
1117
194
1678
110
1354
117
710
187
2322
82
46
222
2986
111
701
188
2320
148
1659
112
1267
122
1681
39
513
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
3.0e-01
1.6e+00
—
—
2.1e+00
1.5e+00
1.4e+00
cases:4.93%
controls:3.69%
cases:4.28%
controls:0.89%
—
—
—
—
cases:1.67%
controls:0.20%
cases:5.77%
controls:1.30%
cases:12.42%
controls:3.46%
15
112
289
2920
13
27
291
3005
—
—
5
6
294
3015
15
38
245
2888
20
76
141
2118
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
5.8e-01
1.3e+00
1.7e+00
—
9.4e-01
8.4e-01
5.2e-01
cases:23.68%
controls:14.74%
cases:22.04%
controls:6.93%
cases:5.92%
controls:1.09%
—
—
cases:2.34%
controls:0.93%
cases:18.08%
controls:8.71%
cases:29.81%
controls:20.15%
72
447
232
2585
67
210
237
2822
18
33
286
2999
—
7
28
292
2993
47
255
213
2671
48
442
113
1752
Supine thorax X-ray examination
GD1QA [2001303648]
1.0e+00
1.9e+00
—
—
—
1.6e+00
4.2e-01
cases:7.57%
controls:2.84%
cases:6.91%
controls:1.12%
—
—
—
—
—
—
cases:6.92%
controls:1.54%
cases:8.70%
controls:5.88%
23
86
281
2946
21
34
283
2998
—
—
—
18
45
242
2881
14
129
147
2065
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
6.1e-01
8.8e-01
1.0e+00
—
1.2e+00
7.3e-01
5.1e-01
cases:49.34%
controls:34.53%
cases:40.46%
controls:21.93%
cases:11.51%
controls:4.49%
—
—
cases:14.05%
controls:4.63%
cases:38.85%
controls:23.44%
cases:57.76%
controls:45.17%
150
1047
154
1985
123
665
181
2367
35
136
269
2896
—
42
140
257
2881
101
686
159
2240
93
991
68
1203
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1.0e+00
1.4e+00
2.0e+00
—
1.6e+00
5.8e-01
2.0e-01
cases:14.47%
controls:5.87%
cases:10.20%
controls:2.61%
cases:2.63%
controls:0.36%
—
—
cases:2.01%
controls:0.43%
cases:6.15%
controls:3.55%
cases:9.32%
controls:7.79%
44
178
260
2854
31
79
273
2953
8
11
296
3021
—
6
13
293
3008
16
104
244
2822
15
171
146
2023
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
7.5e-01
1.2e+00
1.6e+00
—
9.4e-01
9.0e-01
5.9e-02
cases:21.38%
controls:11.35%
cases:17.43%
controls:6.23%
cases:3.95%
controls:0.82%
—
—
cases:3.01%
controls:1.19%
cases:13.85%
controls:6.12%
cases:16.15%
controls:15.36%
65
344
239
2688
53
189
251
2843
12
25
292
3007
—
9
36
290
2985
36
179
224
2747
26
337
135
1857
Physical Medicine And Rehabilitation
25 [38004468]
8.5e-01
1.1e+00
1.9e+00
—
2.5e+00
1.0e+00
6.8e-01
cases:12.50%
controls:5.74%
cases:6.25%
controls:2.21%
cases:1.97%
controls:0.30%
—
—
cases:2.68%
controls:0.23%
cases:4.62%
controls:1.74%
cases:10.56%
controls:5.65%
38
174
266
2858
19
67
285
2965
6
9
298
3023
—
8
7
291
3014
12
51
248
2875
17
124
144
2070
General Surgery
2 [38004447]
8.1e-01
1.4e+00
1.1e+00
—
1.2e+00
1.1e+00
9.9e-01
cases:37.83%
controls:21.37%
cases:22.70%
controls:6.76%
cases:3.29%
controls:1.09%
—
—
cases:3.34%
controls:1.06%
cases:19.23%
controls:7.14%
cases:35.40%
controls:16.91%
115
648
189
2384
69
205
235
2827
10
33
294
2999
—
10
32
289
2989
50
209
210
2717
57
371
104
1823
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
2.1e+00
2.2e+00
—
—
—
—
—
cases:5.59%
controls:0.73%
cases:1.97%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
17
22
287
3010
6
7
298
3025
—
—
—
—
—
Acute cystitis
N30.0 [45601724]
1.2e+00
1.6e+00
—
—
—
1.5e+00
9.0e-01
cases:5.92%
controls:1.85%
cases:4.61%
controls:0.99%
—
—
—
—
—
—
cases:3.46%
controls:0.82%
cases:8.70%
controls:3.74%
18
56
286
2976
14
30
290
3002
—
—
—
9
24
251
2902
14
82
147
2112
Laboratory Visit
OMOP4822461 [32036]
1.1e-01
2.7e-01
9.5e-01
2.4e+00
9.3e-01
1.1e-01
-1.4e-01
cases:43.09%
controls:40.30%
cases:44.74%
controls:38.09%
cases:28.95%
controls:13.56%
cases:9.87%
controls:1.02%
cases:27.76%
controls:13.21%
cases:44.23%
controls:41.49%
cases:48.45%
controls:51.96%
131
1222
173
1810
136
1155
168
1877
88
411
216
2621
30
31
274
3001
83
399
216
2622
115
1214
145
1712
78
1140
83
1054
Noninvasive ventilation
WX725 [2001310828]
1.9e+00
2.3e+00
—
—
—
-1.0e+50
—
cases:3.95%
controls:0.63%
cases:1.97%
controls:0.20%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
12
19
292
3013
6
6
298
3026
—
—
—
0
8
260
2918
—
Repair work or maintenance done on the aid
R5130 [2001310248]
—
—
—
—
—
2.1e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:2.69%
controls:0.34%
cases:7.45%
controls:1.00%
—
—
—
—
—
7
10
253
2916
12
22
149
2172
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
1.3e+00
2.3e+00
—
—
—
—
1.8e+00
cases:3.29%
controls:0.92%
cases:3.29%
controls:0.33%
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.73%
10
28
294
3004
10
10
294
3022
—
—
—
—
7
16
154
2178
sertraline; oral
N06AB06 [21604714]
1.2e+00
1.4e+00
—
—
—
2.3e+00
1.8e+00
cases:2.30%
controls:0.69%
cases:1.64%
controls:0.40%
—
—
—
—
—
—
cases:3.85%
controls:0.41%
cases:6.21%
controls:1.05%
7
21
297
3011
5
12
299
3020
—
—
—
10
12
250
2914
10
23
151
2171
Intubation
WX704 [2001310820]
1.9e+00
2.1e+00
—
—
—
—
1.5e+00
cases:5.59%
controls:0.86%
cases:3.29%
controls:0.40%
—
—
—
—
—
—
—
—
cases:3.11%
controls:0.68%
17
26
287
3006
10
12
294
3020
—
—
—
—
5
15
156
2179
temazepam; oral
N05CD07 [21604642]
7.5e-01
1.0e+00
9.9e-01
—
7.5e-01
1.0e+00
1.3e+00
cases:10.53%
controls:5.28%
cases:9.54%
controls:3.63%
cases:2.63%
controls:0.99%
—
—
cases:1.67%
controls:0.79%
cases:8.85%
controls:3.42%
cases:14.91%
controls:4.65%
32
160
272
2872
29
110
275
2922
8
30
296
3002
—
5
24
294
2997
23
100
237
2826
24
102
137
2092
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
5.3e-01
8.9e-01
1.1e+00
—
1.5e+00
5.2e-01
2.6e-01
cases:19.74%
controls:12.66%
cases:15.79%
controls:7.16%
cases:5.26%
controls:1.85%
—
—
cases:5.69%
controls:1.39%
cases:12.31%
controls:7.69%
cases:20.50%
controls:16.64%
60
384
244
2648
48
217
256
2815
16
56
288
2976
—
17
42
282
2979
32
225
228
2701
33
365
128
1829
Constipation, unspecified
K59.09 [2000502926]
1.6e+00
2.3e+00
—
—
—
—
1.1e+00
cases:3.29%
controls:0.69%
cases:2.30%
controls:0.23%
—
—
—
—
—
—
—
—
cases:4.35%
controls:1.46%
10
21
294
3011
7
7
297
3025
—
—
—
—
7
32
154
2162
acetylsalicylic acid; oral
B01AC06 [21600991]
8.6e-01
9.3e-01
1.1e+00
—
4.5e-01
1.2e+00
9.0e-01
cases:11.51%
controls:5.21%
cases:8.22%
controls:3.43%
cases:3.95%
controls:1.35%
—
—
cases:2.01%
controls:1.29%
cases:10.38%
controls:3.32%
cases:16.15%
controls:7.29%
35
158
269
2874
25
104
279
2928
12
41
292
2991
—
6
39
293
2982
27
97
233
2829
26
160
135
2034
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
5.4e-01
1.5e+00
2.3e+00
—
—
3.5e-01
6.0e-01
cases:2.63%
controls:1.55%
cases:5.26%
controls:1.19%
cases:2.30%
controls:0.23%
—
—
—
—
cases:1.92%
controls:1.37%
cases:8.07%
controls:4.60%
8
47
296
2985
16
36
288
2996
7
7
297
3025
—
—
5
40
255
2886
13
101
148
2093
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
6.4e-01
1.6e+00
2.2e+00
—
—
4.8e-01
5.3e-01
cases:2.96%
controls:1.58%
cases:5.26%
controls:1.15%
cases:1.97%
controls:0.23%
—
—
—
—
cases:1.92%
controls:1.20%
cases:7.45%
controls:4.51%
9
48
295
2984
16
35
288
2997
6
7
298
3025
—
—
5
35
255
2891
12
99
149
2095
Differential panel, method unspecified - Blood
69738-3 [42870588]
4.5e-01
6.9e-01
1.9e+00
—
1.8e+00
6.7e-01
5.1e-01
cases:11.18%
controls:7.42%
cases:7.57%
controls:3.96%
cases:3.62%
controls:0.56%
—
—
cases:3.34%
controls:0.56%
cases:7.69%
controls:4.10%
cases:13.66%
controls:8.71%
34
225
270
2807
23
120
281
2912
11
17
293
3015
—
10
17
289
3004
20
120
240
2806
22
191
139
2003
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
8.1e-01
1.2e+00
1.6e+00
1.0e+50
4.9e-01
6.3e-01
5.4e-01
cases:16.12%
controls:7.88%
cases:11.84%
controls:3.89%
cases:3.95%
controls:0.79%
cases:4.93%
controls:0.00%
cases:1.67%
controls:1.03%
cases:8.46%
controls:4.68%
cases:18.01%
controls:11.39%
49
239
255
2793
36
118
268
2914
12
24
292
3008
15
0
289
3032
5
31
294
2990
22
137
238
2789
29
250
132
1944
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
7.7e-01
1.8e+00
1.9e+00
—
—
1.1e+00
4.3e-01
cases:11.84%
controls:5.84%
cases:13.16%
controls:2.47%
cases:1.97%
controls:0.30%
—
—
—
—
cases:8.08%
controls:2.90%
cases:12.42%
controls:8.48%
36
177
268
2855
40
75
264
2957
6
9
298
3023
—
—
21
85
239
2841
20
186
141
2008
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
5.6e-01
1.6e+00
—
—
—
1.1e+00
9.0e-01
cases:11.18%
controls:6.73%
cases:10.20%
controls:2.24%
—
—
—
—
—
—
cases:8.85%
controls:3.11%
cases:19.25%
controls:8.84%
34
204
270
2828
31
68
273
2964
—
—
—
23
91
237
2835
31
194
130
2000
Treatment-related counselling outside office
SPAT1249 [2001700350]
9.2e-01
9.5e-01
1.0e+00
—
9.9e-01
9.4e-01
7.9e-01
cases:20.07%
controls:9.07%
cases:9.54%
controls:3.92%
cases:2.30%
controls:0.82%
—
—
cases:1.67%
controls:0.63%
cases:8.46%
controls:3.49%
cases:16.77%
controls:8.39%
61
275
243
2757
29
119
275
2913
7
25
297
3007
—
5
19
294
3002
22
102
238
2824
27
184
134
2010
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
8.1e-01
1.4e+00
1.3e+00
—
6.3e-01
4.4e-01
1.3e-01
cases:20.72%
controls:10.46%
cases:18.09%
controls:4.98%
cases:3.95%
controls:1.06%
—
—
cases:1.67%
controls:0.89%
cases:9.23%
controls:6.15%
cases:16.15%
controls:14.45%
63
317
241
2715
55
151
249
2881
12
32
292
3000
—
5
27
294
2994
24
180
236
2746
26
317
135
1877
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
5.2e-01
1.3e+00
2.3e+00
—
—
5.6e-01
5.4e-01
cases:3.95%
controls:2.37%
cases:5.92%
controls:1.75%
cases:2.96%
controls:0.30%
—
—
—
—
cases:3.46%
controls:2.02%
cases:9.94%
controls:6.06%
12
72
292
2960
18
53
286
2979
9
9
295
3023
—
—
9
59
251
2867
16
133
145
2061
calcium (different salts in combination); oral
A12AA20 [21600872]
8.1e-01
1.0e+00
9.6e-01
—
7.6e-01
7.4e-01
3.4e-01
cases:23.36%
controls:11.94%
cases:23.36%
controls:9.96%
cases:7.89%
controls:3.17%
—
—
cases:7.02%
controls:3.41%
cases:20.00%
controls:10.70%
cases:20.50%
controls:15.54%
71
362
233
2670
71
302
233
2730
24
96
280
2936
—
21
103
278
2918
52
313
208
2613
33
341
128
1853
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
7.3e-01
—
—
1.0e+50
—
2.0e+00
1.5e+00
cases:3.62%
controls:1.78%
—
—
—
—
cases:6.25%
controls:0.00%
—
—
cases:5.00%
controls:0.68%
cases:9.32%
controls:2.32%
11
54
293
2978
—
—
19
0
285
3032
—
13
20
247
2906
15
51
146
2143
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
6.1e-01
1.3e+00
1.8e+00
—
2.2e+00
3.0e-01
4.5e-02
cases:10.20%
controls:5.80%
cases:7.89%
controls:2.31%
cases:1.97%
controls:0.33%
—
—
cases:2.34%
controls:0.26%
cases:3.46%
controls:2.60%
cases:8.07%
controls:7.75%
31
176
273
2856
24
70
280
2962
6
10
298
3022
—
7
8
292
3013
9
76
251
2850
13
170
148
2024
cefalexin; oral
J01DB01 [21602870]
5.4e-01
5.7e-01
6.2e-01
—
1.6e+00
6.3e-01
7.4e-01
cases:39.80%
controls:27.87%
cases:14.80%
controls:8.94%
cases:2.30%
controls:1.25%
—
—
cases:4.35%
controls:0.93%
cases:15.77%
controls:9.09%
cases:44.72%
controls:27.80%
121
845
183
2187
45
271
259
2761
7
38
297
2994
—
13
28
286
2993
41
266
219
2660
72
610
89
1584
nitrofurantoin; oral
J01XE01 [21603058]
9.7e-01
1.2e+00
—
—
—
1.5e+00
1.1e+00
cases:6.58%
controls:2.61%
cases:2.63%
controls:0.79%
—
—
—
—
—
—
cases:3.46%
controls:0.82%
cases:9.32%
controls:3.46%
20
79
284
2953
8
24
296
3008
—
—
—
9
24
251
2902
15
76
146
2118
oxycodone and naloxone; oral
N02AA55 [21604265]
1.4e+00
2.1e+00
—
—
—
1.2e+00
5.5e-01
cases:6.91%
controls:1.88%
cases:4.28%
controls:0.53%
—
—
—
—
—
—
cases:3.46%
controls:1.03%
cases:6.21%
controls:3.69%
21
57
283
2975
13
16
291
3016
—
—
—
9
30
251
2896
10
81
151
2113
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.6e-01
9.9e-01
1.4e+00
—
6.7e-01
5.5e-01
5.0e-02
cases:30.26%
controls:19.79%
cases:25.99%
controls:11.51%
cases:7.89%
controls:2.14%
—
—
cases:4.68%
controls:2.45%
cases:20.77%
controls:13.09%
cases:27.33%
controls:26.34%
92
600
212
2432
79
349
225
2683
24
65
280
2967
—
14
74
285
2947
54
383
206
2543
44
578
117
1616
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.5e+00
2.0e+00
—
—
—
—
8.1e-01
cases:6.91%
controls:1.62%
cases:4.28%
controls:0.63%
—
—
—
—
—
—
—
—
cases:6.21%
controls:2.87%
21
49
283
2983
13
19
291
3013
—
—
—
—
10
63
151
2131
pivmecillinam; oral
J01CA08 [21602827]
6.2e-01
8.8e-01
1.6e+00
—
1.2e+00
9.4e-01
1.0e+00
cases:15.79%
controls:9.20%
cases:8.88%
controls:3.89%
cases:2.30%
controls:0.46%
—
—
cases:2.01%
controls:0.63%
cases:9.23%
controls:3.83%
cases:25.47%
controls:11.12%
48
279
256
2753
27
118
277
2914
7
14
297
3018
—
6
19
293
3002
24
112
236
2814
41
244
120
1950
Weakness/tiredness general
A04 [2002000145]
1.1e+00
7.3e-01
2.3e+00
—
—
7.9e-01
5.1e-01
cases:4.93%
controls:1.68%
cases:2.63%
controls:1.29%
cases:1.97%
controls:0.20%
—
—
—
—
cases:2.31%
controls:1.06%
cases:6.21%
controls:3.83%
15
51
289
2981
8
39
296
2993
6
6
298
3026
—
—
6
31
254
2895
10
84
151
2110
Overall medication plan or its review
SPAT1252 [2001700353]
1.4e+00
1.8e+00
—
—
—
2.0e+00
1.4e+00
cases:3.62%
controls:0.96%
cases:1.97%
controls:0.33%
—
—
—
—
—
—
cases:3.46%
controls:0.48%
cases:5.59%
controls:1.46%
11
29
293
3003
6
10
298
3022
—
—
—
9
14
251
2912
9
32
152
2162
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
4.3e-02
1.2e+00
2.1e+00
—
—
5.3e-01
9.2e-02
cases:7.89%
controls:7.59%
cases:9.54%
controls:3.13%
cases:3.95%
controls:0.49%
—
—
—
—
cases:5.77%
controls:3.49%
cases:13.04%
controls:12.03%
24
230
280
2802
29
95
275
2937
12
15
292
3017
—
—
15
102
245
2824
21
264
140
1930
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
9.6e-01
1.0e+00
—
—
1.7e+00
7.7e-01
1.3e+00
cases:17.11%
controls:7.32%
cases:6.25%
controls:2.31%
—
—
—
—
cases:1.67%
controls:0.30%
cases:5.77%
controls:2.77%
cases:22.98%
controls:7.70%
52
222
252
2810
19
70
285
2962
—
—
5
9
294
3012
15
81
245
2845
37
169
124
2025
Cathetrisation of artery
TPH07 [2001309747]
1.5e+00
1.7e+00
—
—
—
—
—
cases:6.58%
controls:1.58%
cases:3.29%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
20
48
284
2984
10
18
294
3014
—
—
—
—
—
ferrous glycine sulfate; oral
B03AA01 [21601080]
1.6e+00
1.4e+00
—
—
—
1.6e+00
8.5e-01
cases:4.61%
controls:0.96%
cases:2.30%
controls:0.59%
—
—
—
—
—
—
cases:4.23%
controls:0.89%
cases:4.97%
controls:2.19%
14
29
290
3003
7
18
297
3014
—
—
—
11
26
249
2900
8
48
153
2146
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
1.1e+00
1.1e+00
—
—
2.0e+00
1.4e+00
1.0e+00
cases:7.24%
controls:2.47%
cases:3.29%
controls:1.09%
—
—
—
—
cases:2.01%
controls:0.26%
cases:3.46%
controls:0.89%
cases:7.45%
controls:2.78%
22
75
282
2957
10
33
294
2999
—
—
6
8
293
3013
9
26
251
2900
12
61
149
2133
Atherosclerotic cardiovascular disease, so described
I25.0 [45552783]
1.3e+00
1.9e+00
—
—
—
1.5e+00
7.7e-01
cases:3.95%
controls:1.15%
cases:2.96%
controls:0.46%
—
—
—
—
—
—
cases:2.31%
controls:0.51%
cases:3.11%
controls:1.46%
12
35
292
2997
9
14
295
3018
—
—
—
6
15
254
2911
5
32
156
2162
Monocytes/Leukocytes in Blood
26485-3 [3019069]
2.7e-01
4.6e-01
1.5e+00
—
1.6e+00
4.5e-01
2.3e-01
cases:12.83%
controls:10.13%
cases:8.88%
controls:5.77%
cases:3.95%
controls:0.92%
—
—
cases:3.34%
controls:0.70%
cases:9.23%
controls:6.08%
cases:16.15%
controls:13.22%
39
307
265
2725
27
175
277
2857
12
28
292
3004
—
10
21
289
3000
24
178
236
2748
26
290
135
1904
Basophils/Leukocytes in Blood
30180-4 [3022096]
2.7e-01
4.3e-01
1.5e+00
—
1.6e+00
3.4e-01
1.8e-01
cases:12.83%
controls:10.06%
cases:8.55%
controls:5.74%
cases:3.95%
controls:0.92%
—
—
cases:3.34%
controls:0.70%
cases:8.46%
controls:6.15%
cases:15.53%
controls:13.35%
39
305
265
2727
26
174
278
2858
12
28
292
3004
—
10
21
289
3000
22
180
238
2746
25
293
136
1901
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
2.7e-01
4.3e-01
1.5e+00
—
1.6e+00
4.0e-01
1.9e-01
cases:12.83%
controls:10.06%
cases:8.55%
controls:5.74%
cases:3.95%
controls:0.92%
—
—
cases:3.34%
controls:0.70%
cases:8.85%
controls:6.12%
cases:15.53%
controls:13.22%
39
305
265
2727
26
174
278
2858
12
28
292
3004
—
10
21
289
3000
23
179
237
2747
25
290
136
1904
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
8.5e-01
1.2e+00
—
—
—
1.0e+00
4.3e-01
cases:13.49%
controls:6.23%
cases:6.58%
controls:2.08%
—
—
—
—
—
—
cases:6.92%
controls:2.63%
cases:10.56%
controls:7.11%
41
189
263
2843
20
63
284
2969
—
—
—
18
77
242
2849
17
156
144
2038
folic acid; oral, parenteral
B03BB01 [21601129]
1.1e+00
9.3e-01
—
—
1.7e+00
1.3e+00
—
cases:3.62%
controls:1.22%
cases:2.96%
controls:1.19%
—
—
—
—
cases:2.68%
controls:0.50%
cases:5.38%
controls:1.47%
—
—
11
37
293
2995
9
36
295
2996
—
—
8
15
291
3006
14
43
246
2883
—
folic acid
V04CX02 [715877]
1.1e+00
9.3e-01
—
—
1.7e+00
1.3e+00
—
cases:3.62%
controls:1.22%
cases:2.96%
controls:1.19%
—
—
—
—
cases:2.68%
controls:0.50%
cases:5.38%
controls:1.47%
—
—
11
37
293
2995
9
36
295
2996
—
—
8
15
291
3006
14
43
246
2883
—
Urinary tract infection, site not specified
N39.0 [45548665]
1.2e+00
1.8e+00
—
1.0e+50
—
1.3e+00
9.5e-01
cases:7.57%
controls:2.41%
cases:5.92%
controls:0.99%
—
—
cases:1.64%
controls:0.00%
—
—
cases:3.46%
controls:0.92%
cases:9.32%
controls:3.83%
23
73
281
2959
18
30
286
3002
—
5
0
299
3032
—
9
27
251
2899
15
84
146
2110
lansoprazole; oral
A02BC03 [21600098]
8.5e-01
1.1e+00
—
—
1.3e+00
1.1e+00
6.9e-01
cases:12.83%
controls:5.90%
cases:8.22%
controls:2.90%
—
—
—
—
cases:2.01%
controls:0.56%
cases:8.08%
controls:2.97%
cases:11.80%
controls:6.29%
39
179
265
2853
25
88
279
2944
—
—
6
17
293
3004
21
87
239
2839
19
138
142
2056
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
2.1e-01
4.9e-01
1.5e+00
—
1.5e+00
2.8e-01
2.6e-01
cases:11.84%
controls:9.83%
cases:8.55%
controls:5.41%
cases:3.62%
controls:0.86%
—
—
cases:3.34%
controls:0.76%
cases:8.08%
controls:6.22%
cases:16.15%
controls:12.90%
36
298
268
2734
26
164
278
2868
11
26
293
3006
—
10
23
289
2998
21
182
239
2744
26
283
135
1911
Epilepsy, unspecified
G40.9 [45562083]
3.0e+00
—
—
—
—
—
1.5e+00
cases:4.28%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
cases:3.11%
controls:0.68%
13
7
291
3025
—
—
—
—
—
5
15
156
2179
Heart failure, unspecified
I50.9 [45576879]
9.2e-01
9.9e-01
1.3e+00
—
—
1.0e+00
4.5e-02
cases:9.21%
controls:3.89%
cases:6.25%
controls:2.41%
cases:2.30%
controls:0.66%
—
—
—
—
cases:7.31%
controls:2.70%
cases:8.07%
controls:7.75%
28
118
276
2914
19
73
285
2959
7
20
297
3012
—
—
19
79
241
2847
13
170
148
2024
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
2.7e-01
4.5e-01
1.4e+00
—
1.5e+00
3.7e-01
1.9e-01
cases:12.83%
controls:10.06%
cases:8.88%
controls:5.87%
cases:3.95%
controls:0.96%
—
—
cases:3.34%
controls:0.79%
cases:8.85%
controls:6.29%
cases:16.15%
controls:13.76%
39
305
265
2727
27
178
277
2854
12
29
292
3003
—
10
24
289
2997
23
184
237
2742
26
302
135
1892
Vascular Surgery
77 [38004496]
7.9e-01
9.8e-01
—
—
2.1e+00
1.1e+00
7.1e-01
cases:7.89%
controls:3.76%
cases:4.28%
controls:1.65%
—
—
—
—
cases:2.68%
controls:0.33%
cases:3.85%
controls:1.30%
cases:9.32%
controls:4.79%
24
114
280
2918
13
50
291
2982
—
—
8
10
291
3011
10
38
250
2888
15
105
146
2089
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
5.7e-01
1.3e+00
1.6e+00
—
1.3e+00
4.0e-01
6.6e-02
cases:13.49%
controls:8.08%
cases:13.49%
controls:4.22%
cases:2.63%
controls:0.53%
—
—
cases:2.34%
controls:0.63%
cases:7.31%
controls:5.02%
cases:14.29%
controls:13.49%
41
245
263
2787
41
128
263
2904
8
16
296
3016
—
7
19
292
3002
19
147
241
2779
23
296
138
1898
mirtazapine; oral
N06AX11 [21604740]
9.5e-01
8.2e-01
—
—
1.2e+00
1.0e+00
6.4e-01
cases:14.14%
controls:6.00%
cases:8.88%
controls:4.12%
—
—
—
—
cases:3.68%
controls:1.19%
cases:11.54%
controls:4.44%
cases:15.53%
controls:8.84%
43
182
261
2850
27
125
277
2907
—
—
11
36
288
2985
30
130
230
2796
25
194
136
2000
denosumab; parenteral
M05BX04 [21604169]
1.4e+00
1.1e+00
—
—
2.1e+00
1.4e+00
—
cases:3.29%
controls:0.82%
cases:2.63%
controls:0.92%
—
—
—
—
cases:1.67%
controls:0.20%
cases:4.23%
controls:1.09%
—
—
10
25
294
3007
8
28
296
3004
—
—
5
6
294
3015
11
32
249
2894
—
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
2.7e-01
9.2e-01
1.8e+00
—
1.3e+00
2.9e-01
-3.5e-02
cases:7.24%
controls:5.64%
cases:6.91%
controls:2.87%
cases:3.62%
controls:0.59%
—
—
cases:2.34%
controls:0.63%
cases:4.62%
controls:3.49%
cases:8.70%
controls:8.98%
22
171
282
2861
21
87
283
2945
11
18
293
3014
—
7
19
292
3002
12
102
248
2824
14
197
147
1997
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
1.2e+00
1.5e+00
—
—
—
—
—
cases:4.61%
controls:1.45%
cases:3.29%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
14
44
290
2988
10
22
294
3010
—
—
—
—
—
Respiratory and circulatory monitoring
WX700 [2001310817]
1.1e+00
1.6e+00
—
—
—
—
5.4e-01
cases:6.58%
controls:2.34%
cases:3.62%
controls:0.73%
—
—
—
—
—
—
—
—
cases:4.97%
controls:2.96%
20
71
284
2961
11
22
293
3010
—
—
—
—
8
65
153
2129
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.0e+00
1.6e+00
—
—
1.7e+00
1.2e+00
-4.0e-02
cases:6.91%
controls:2.54%
cases:4.61%
controls:0.92%
—
—
—
—
cases:1.67%
controls:0.30%
cases:3.46%
controls:1.06%
cases:3.73%
controls:3.87%
21
77
283
2955
14
28
290
3004
—
—
5
9
294
3012
9
31
251
2895
6
85
155
2109
levomepromazine; oral, parenteral
N05AA02 [21604493]
1.4e+00
2.7e+00
—
—
—
—
—
cases:1.64%
controls:0.43%
cases:2.30%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
5
13
299
3019
7
5
297
3027
—
—
—
—
—
Valproate [Moles/volume] in Serum or Plasma
14946-8 [3009466]
2.7e+00
2.3e+00
—
—
—
—
2.2e+00
cases:2.30%
controls:0.16%
cases:1.64%
controls:0.16%
—
—
—
—
—
—
—
—
cases:3.11%
controls:0.36%
7
5
297
3027
5
5
299
3027
—
—
—
—
5
8
156
2186
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
-2.9e-01
1.0e+00
1.6e+00
—
1.6e+00
5.1e-01
7.5e-02
cases:2.96%
controls:3.92%
cases:5.59%
controls:2.11%
cases:2.63%
controls:0.53%
—
—
cases:2.01%
controls:0.43%
cases:5.00%
controls:3.08%
cases:9.32%
controls:8.71%
9
119
295
2913
17
64
287
2968
8
16
296
3016
—
6
13
293
3008
13
90
247
2836
15
191
146
2003
Cathetrisation of vein
TPH04 [2001309597]
1.0e+00
1.5e+00
—
—
—
5.7e-01
1.1e-01
cases:9.54%
controls:3.56%
cases:4.61%
controls:1.02%
—
—
—
—
—
—
cases:1.92%
controls:1.09%
cases:4.97%
controls:4.47%
29
108
275
2924
14
31
290
3001
—
—
—
5
32
255
2894
8
98
153
2096
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
2.1e-01
9.9e-01
1.6e+00
—
1.3e+00
4.2e-01
-6.6e-02
cases:5.92%
controls:4.85%
cases:6.25%
controls:2.41%
cases:2.96%
controls:0.63%
—
—
cases:2.34%
controls:0.63%
cases:5.00%
controls:3.35%
cases:9.32%
controls:9.89%
18
147
286
2885
19
73
285
2959
9
19
295
3013
—
7
19
292
3002
13
98
247
2828
15
217
146
1977
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
4.7e-01
1.1e+00
—
—
—
1.5e+00
7.2e-01
cases:10.20%
controls:6.60%
cases:5.59%
controls:1.91%
—
—
—
—
—
—
cases:7.69%
controls:1.91%
cases:13.66%
controls:7.16%
31
200
273
2832
17
58
287
2974
—
—
—
20
56
240
2870
22
157
139
2037
Office Visit
OMOP4822458 [581477]
1.2e+00
1.4e+00
—
—
—
4.8e-01
6.3e-01
cases:24.34%
controls:8.94%
cases:9.87%
controls:2.70%
—
—
—
—
—
—
cases:4.23%
controls:2.67%
cases:15.53%
controls:8.93%
74
271
230
2761
30
82
274
2950
—
—
—
11
78
249
2848
25
196
136
1998
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
96119-3 [36032419]
2.6e+00
—
—
—
—
—
—
cases:3.29%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
—
—
10
8
294
3024
—
—
—
—
—
—
pH of Urine
2756-5 [3015736]
2.0e-01
1.1e+00
1.5e+00
—
1.4e+00
5.5e-01
1.3e-02
cases:9.87%
controls:8.25%
cases:10.53%
controls:3.92%
cases:3.62%
controls:0.86%
—
—
cases:3.01%
controls:0.79%
cases:8.85%
controls:5.30%
cases:15.53%
controls:15.36%
30
250
274
2782
32
119
272
2913
11
26
293
3006
—
9
24
290
2997
23
155
237
2771
25
337
136
1857
Emergency Medicine
93 [38004510]
-2.8e-01
6.5e-01
1.9e+00
—
1.0e+00
1.1e-01
-2.5e-01
cases:11.84%
controls:15.11%
cases:13.82%
controls:7.75%
cases:5.92%
controls:0.96%
—
—
cases:3.68%
controls:1.32%
cases:10.38%
controls:9.43%
cases:18.63%
controls:22.70%
36
458
268
2574
42
235
262
2797
18
29
286
3003
—
11
40
288
2981
27
276
233
2650
30
498
131
1696
Functional capacity evaluation
443351003 [40481051]
8.9e-01
1.6e+00
—
—
—
7.0e-01
5.8e-01
cases:7.89%
controls:3.40%
cases:7.57%
controls:1.58%
—
—
—
—
—
—
cases:3.46%
controls:1.74%
cases:7.45%
controls:4.33%
24
103
280
2929
23
48
281
2984
—
—
—
9
51
251
2875
12
95
149
2099
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
G40.29 [2000502142]
1.9e+00
—
—
—
—
—
2.5e+00
cases:1.97%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.36%
6
9
298
3023
—
—
—
—
—
7
8
154
2186
hydrocortisone
C05AA01 [21601608]
4.2e-01
5.4e-01
—
—
2.5e+00
4.3e-01
6.5e-01
cases:11.51%
controls:7.85%
cases:4.28%
controls:2.54%
—
—
—
—
cases:2.01%
controls:0.17%
cases:4.23%
controls:2.80%
cases:13.66%
controls:7.61%
35
238
269
2794
13
77
291
2955
—
—
6
5
293
3016
11
82
249
2844
22
167
139
2027
hydrocortisone
A07EA02 [21600654]
4.2e-01
5.4e-01
—
—
2.5e+00
4.3e-01
6.5e-01
cases:11.51%
controls:7.85%
cases:4.28%
controls:2.54%
—
—
—
—
cases:2.01%
controls:0.17%
cases:4.23%
controls:2.80%
cases:13.66%
controls:7.61%
35
238
269
2794
13
77
291
2955
—
—
6
5
293
3016
11
82
249
2844
22
167
139
2027
hydrocortisone
S02BA01 [21605166]
5.5e-01
6.8e-01
—
—
2.5e+00
5.9e-01
5.9e-01
cases:11.51%
controls:6.99%
cases:4.28%
controls:2.21%
—
—
—
—
cases:2.01%
controls:0.17%
cases:4.23%
controls:2.39%
cases:11.80%
controls:6.88%
35
212
269
2820
13
67
291
2965
—
—
6
5
293
3016
11
70
249
2856
19
151
142
2043
hydrocortisone
D07AA02 [21602102]
4.3e-01
5.8e-01
—
—
2.5e+00
4.3e-01
6.1e-01
cases:11.51%
controls:7.82%
cases:4.28%
controls:2.44%
—
—
—
—
cases:2.01%
controls:0.17%
cases:4.23%
controls:2.80%
cases:13.04%
controls:7.57%
35
237
269
2795
13
74
291
2958
—
—
6
5
293
3016
11
82
249
2844
21
166
140
2028
hydrocortisone butyrate
D07AB02 [21602106]
4.3e-01
5.8e-01
—
—
2.5e+00
4.3e-01
6.1e-01
cases:11.51%
controls:7.82%
cases:4.28%
controls:2.44%
—
—
—
—
cases:2.01%
controls:0.17%
cases:4.23%
controls:2.80%
cases:13.04%
controls:7.57%
35
237
269
2795
13
74
291
2958
—
—
6
5
293
3016
11
82
249
2844
21
166
140
2028
hydrocortisone buteprate
D07AB11 [21602115]
4.3e-01
5.8e-01
—
—
2.5e+00
4.3e-01
6.1e-01
cases:11.51%
controls:7.82%
cases:4.28%
controls:2.44%
—
—
—
—
cases:2.01%
controls:0.17%
cases:4.23%
controls:2.80%
cases:13.04%
controls:7.57%
35
237
269
2795
13
74
291
2958
—
—
6
5
293
3016
11
82
249
2844
21
166
140
2028
hydrocortisone aceponate
D07AC16 [21602135]
4.3e-01
5.8e-01
—
—
2.5e+00
4.3e-01
6.1e-01
cases:11.51%
controls:7.82%
cases:4.28%
controls:2.44%
—
—
—
—
cases:2.01%
controls:0.17%
cases:4.23%
controls:2.80%
cases:13.04%
controls:7.57%
35
237
269
2795
13
74
291
2958
—
—
6
5
293
3016
11
82
249
2844
21
166
140
2028
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay
97097-0 [36033641]
2.5e+00
—
—
—
—
—
—
cases:1.97%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
298
3027
—
—
—
—
—
—
Parkinsonism
N87 [2002000787]
2.5e+00
—
—
—
—
—
-1.0e+50
cases:1.97%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
6
5
298
3027
—
—
—
—
—
0
10
161
2184
Ultrasound oculometry
CA1ME [2001300876]
2.5e+00
—
—
—
—
—
—
cases:1.97%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
298
3027
—
—
—
—
—
—
Epilepsy
G40 [45595935]
2.5e+00
—
—
—
—
—
—
cases:2.63%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
8
7
296
3025
—
—
—
—
—
—
Orthopedic Surgery
20 [38004465]
3.0e-01
9.2e-01
1.5e+00
—
1.0e+00
3.8e-01
-2.0e-01
cases:20.39%
controls:15.93%
cases:13.16%
controls:5.67%
cases:2.96%
controls:0.66%
—
—
cases:2.68%
controls:0.96%
cases:8.08%
controls:5.67%
cases:13.66%
controls:16.13%
62
483
242
2549
40
172
264
2860
9
20
295
3012
—
8
29
291
2992
21
166
239
2760
22
354
139
1840
Atherosclerotic heart disease
I25.1 [45596196]
4.6e-01
8.7e-01
1.6e+00
—
1.2e+00
3.3e-01
-4.8e-02
cases:12.17%
controls:8.08%
cases:9.54%
controls:4.22%
cases:2.96%
controls:0.63%
—
—
cases:3.01%
controls:0.96%
cases:6.92%
controls:5.06%
cases:11.18%
controls:11.67%
37
245
267
2787
29
128
275
2904
9
19
295
3013
—
9
29
290
2992
18
148
242
2778
18
256
143
1938
Monitoring of emergency patient
SPAT1104 [2001700205]
1.1e+00
—
—
—
—
2.4e+00
—
cases:2.63%
controls:0.86%
—
—
—
—
—
—
—
—
cases:2.69%
controls:0.24%
—
—
8
26
296
3006
—
—
—
—
7
7
253
2919
—
Urination problems other
U05 [2002001140]
1.4e+00
—
—
—
—
2.4e+00
—
cases:2.96%
controls:0.73%
—
—
—
—
—
—
—
—
cases:1.92%
controls:0.17%
—
—
9
22
295
3010
—
—
—
—
5
5
255
2921
—
INR in Blood by Coagulation assay
34714-6 [3032080]
4.0e-01
8.8e-01
8.7e-01
—
8.0e-01
6.6e-01
-1.4e-03
cases:19.41%
controls:13.95%
cases:17.11%
controls:7.85%
cases:7.24%
controls:3.17%
—
—
cases:7.02%
controls:3.28%
cases:15.00%
controls:8.34%
cases:17.39%
controls:17.41%
59
423
245
2609
52
238
252
2794
22
96
282
2936
—
21
99
278
2922
39
244
221
2682
28
382
133
1812
Bacteria identified in Isolate by Culture
43409-2 [3042936]
9.6e-01
1.4e+00
—
—
—
8.2e-01
5.7e-01
cases:5.92%
controls:2.34%
cases:3.95%
controls:0.96%
—
—
—
—
—
—
cases:2.31%
controls:1.03%
cases:5.59%
controls:3.24%
18
71
286
2961
12
29
292
3003
—
—
—
6
30
254
2896
9
71
152
2123
Decubitus ulcer and pressure area
L89 [45601235]
—
2.3e+00
—
—
—
—
2.4e+00
—
—
cases:1.64%
controls:0.16%
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.41%
—
5
5
299
3027
—
—
—
—
7
9
154
2185
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
1.0e+00
1.3e+00
1.3e+00
—
1.4e+00
6.7e-01
8.8e-02
cases:18.42%
controls:7.49%
cases:10.20%
controls:2.97%
cases:2.30%
controls:0.66%
—
—
cases:1.67%
controls:0.40%
cases:7.31%
controls:3.86%
cases:10.56%
controls:9.75%
56
227
248
2805
31
90
273
2942
7
20
297
3012
—
5
12
294
3009
19
113
241
2813
17
214
144
1980
Traumatic subdural haemorrhage
S06.5 [45563422]
—
2.3e+00
—
—
—
—
—
—
—
cases:2.63%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
—
8
8
296
3024
—
—
—
—
—
High dependency care
WX882 [2001310847]
2.3e+00
—
—
—
—
—
—
cases:2.63%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
—
—
8
8
296
3024
—
—
—
—
—
—
Psychological sympt/compl other
P29 [2002000823]
2.3e+00
—
—
—
—
—
—
cases:2.63%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
—
—
8
8
296
3024
—
—
—
—
—
—
Type 1 diabetes mellitus, With multiple complications
E10.7 [45571655]
2.3e+00
—
—
—
—
—
—
cases:1.97%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
298
3026
—
—
—
—
—
—
Body temperature
8310-5 [3020891]
—
2.3e+00
—
—
—
—
8.1e-01
—
—
cases:1.97%
controls:0.20%
—
—
—
—
—
—
—
—
cases:3.73%
controls:1.69%
—
6
6
298
3026
—
—
—
—
6
37
155
2157
Dementia in Alzheimer disease, unspecified and Alzheimer disease, unspecified
F00.9*G30.9 [2000503852]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.11%
controls:0.32%
—
—
—
—
—
—
5
7
156
2187
Sequelae of other and unspecified cerebrovascular diseases
I69.8 [45538414]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.11%
controls:0.32%
—
—
—
—
—
—
5
7
156
2187
Organisation of medication
SPAT1251 [2001700352]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.11%
controls:0.32%
—
—
—
—
—
—
5
7
156
2187
Other Alzheimer disease
G30.8 [45605532]
1.7e+00
—
—
—
—
2.3e+00
8.4e-01
cases:1.64%
controls:0.30%
—
—
—
—
—
—
—
—
cases:2.31%
controls:0.24%
cases:3.11%
controls:1.37%
5
9
299
3023
—
—
—
—
6
7
254
2919
5
30
156
2164
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
5.6e-01
1.2e+00
1.7e+00
—
—
1.0e+00
-1.8e-01
cases:10.86%
controls:6.50%
cases:9.21%
controls:2.84%
cases:1.97%
controls:0.36%
—
—
—
—
cases:6.92%
controls:2.67%
cases:6.83%
controls:8.07%
33
197
271
2835
28
86
276
2946
6
11
298
3021
—
—
18
78
242
2848
11
177
150
2017
pH of Serum or Plasma
2753-2 [3018418]
5.5e-01
1.2e+00
1.5e+00
—
1.2e+00
1.0e+00
3.4e-02
cases:11.84%
controls:7.19%
cases:11.84%
controls:3.89%
cases:2.63%
controls:0.63%
—
—
cases:2.34%
controls:0.73%
cases:9.23%
controls:3.49%
cases:11.18%
controls:10.85%
36
218
268
2814
36
118
268
2914
8
19
296
3013
—
7
22
292
2999
24
102
236
2824
18
238
143
1956
Swollen ankles/oedema
K07 [2002000550]
7.4e-01
2.2e+00
—
—
—
—
—
cases:1.64%
controls:0.79%
cases:2.30%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
5
24
299
3008
7
8
297
3024
—
—
—
—
—
Disorientation, unspecified
R41.0 [45558469]
2.2e+00
—
—
—
—
—
-1.0e+50
cases:2.30%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
7
8
297
3024
—
—
—
—
—
0
21
161
2173
Supplier / Service Provider
OMOP5117446 [33004]
-2.0e-01
-3.1e-01
-1.0e+50
—
—
—
2.2e+00
cases:16.12%
controls:19.06%
cases:4.28%
controls:5.74%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:7.45%
controls:0.91%
49
578
255
2454
13
174
291
2858
0
13
304
3019
—
—
—
12
20
149
2174
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.4e-01
4.8e-01
9.3e-01
—
7.5e-01
1.2e-01
-1.6e-01
cases:37.83%
controls:34.50%
cases:35.53%
controls:25.40%
cases:10.53%
controls:4.42%
—
—
cases:10.03%
controls:5.00%
cases:30.77%
controls:28.30%
cases:40.99%
controls:44.85%
115
1046
189
1986
108
770
196
2262
32
134
272
2898
—
30
151
269
2870
80
828
180
2098
66
984
95
1210
Lower extremity artery ultrasound examination with Doppler method
PD4DE [2001309218]
2.2e+00
—
—
—
—
—
—
cases:1.97%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
298
3025
—
—
—
—
—
—
More than three and less than five hours
ZXE20 [2001311408]
7.5e-01
2.2e+00
—
—
—
—
—
cases:3.29%
controls:1.58%
cases:1.97%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
10
48
294
2984
6
7
298
3025
—
—
—
—
—
Pulmonary Disease
29 [38004472]
6.7e-01
5.7e-01
1.5e+00
—
1.0e+00
4.2e-01
2.4e-01
cases:18.42%
controls:10.36%
cases:9.21%
controls:5.44%
cases:4.93%
controls:1.15%
—
—
cases:3.34%
controls:1.22%
cases:8.46%
controls:5.71%
cases:14.91%
controls:12.08%
56
314
248
2718
28
165
276
2867
15
35
289
2997
—
10
37
289
2984
22
167
238
2759
24
265
137
1929
Exposure to unspecified factor
X59 [45756412]
6.6e-01
2.1e+00
—
—
—
9.5e-01
1.1e+00
cases:3.95%
controls:2.08%
cases:3.95%
controls:0.49%
—
—
—
—
—
—
cases:1.92%
controls:0.75%
cases:7.45%
controls:2.69%
12
63
292
2969
12
15
292
3017
—
—
—
5
22
255
2904
12
59
149
2135
Ammonium ion [Moles/volume] in Plasma
1845-7 [3023183]
2.1e+00
—
—
—
—
—
—
cases:2.63%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
8
10
296
3022
—
—
—
—
—
—
Neuropsychological investigation
XA800 [2001300412]
2.1e+00
—
—
—
—
—
—
cases:2.63%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
8
10
296
3022
—
—
—
—
—
—
Other and unspecified abnormalities of gait and mobility
R26.8 [45597174]
2.1e+00
—
—
—
—
—
—
cases:2.63%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
8
10
296
3022
—
—
—
—
—
—
Major dressing of wound of skin of lower limb
QDB10 [2001309970]
2.1e+00
1.7e+00
—
—
—
—
—
cases:3.62%
controls:0.46%
cases:1.64%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
11
14
293
3018
5
9
299
3023
—
—
—
—
—
Infection following a procedure, not elsewhere classified
T81.4 [45575538]
1.3e+00
2.1e+00
—
—
—
—
—
cases:3.29%
controls:0.96%
cases:2.30%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
10
29
294
3003
7
9
297
3023
—
—
—
—
—
Polymyalgia rheumatica
M35.3 [45533830]
1.4e+00
2.1e+00
—
—
—
1.7e+00
—
cases:2.63%
controls:0.66%
cases:2.30%
controls:0.30%
—
—
—
—
—
—
cases:1.92%
controls:0.34%
—
—
8
20
296
3012
7
9
297
3023
—
—
—
5
10
255
2916
—
tranexamic acid; oral, parenteral
B02AA02 [21601036]
8.1e-01
2.1e+00
—
—
—
—
—
cases:1.97%
controls:0.89%
cases:2.30%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
6
27
298
3005
7
9
297
3023
—
—
—
—
—
Other administrative function
SPAT1281 [2001700382]
5.4e-01
-1.0e+50
—
—
—
—
2.0e+00
cases:1.97%
controls:1.15%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.59%
6
35
298
2997
0
11
304
3021
—
—
—
—
7
13
154
2181
Delirium, unspecified
F05.9 [45591078]
2.0e+00
—
—
—
—
—
-1.0e+50
cases:1.97%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
6
8
298
3024
—
—
—
—
—
0
14
161
2180
Chronic respiratory failure
J96.1 [45557632]
1.6e+00
2.0e+00
—
—
—
—
—
cases:1.64%
controls:0.33%
cases:1.97%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
5
10
299
3022
6
8
298
3024
—
—
—
—
—
Varicose veins of lower extremities with ulcer
I83.0 [45557601]
2.0e+00
—
—
—
—
—
—
cases:1.97%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
298
3024
—
—
—
—
—
—
Home visit
WYA20 [2001310873]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.59%
controls:0.77%
—
—
—
—
—
—
9
17
152
2177
Chronic ulcer skin
S97 [2002001061]
2.0e+00
1.7e+00
—
—
—
1.8e+00
1.3e+00
cases:5.59%
controls:0.79%
cases:2.30%
controls:0.43%
—
—
—
—
—
—
cases:2.31%
controls:0.38%
cases:4.35%
controls:1.28%
17
24
287
3008
7
13
297
3019
—
—
—
6
11
254
2915
7
28
154
2166
Exposure to other specified factors
X58 [45756411]
4.6e-01
2.0e+00
—
—
—
—
—
cases:1.97%
controls:1.25%
cases:2.30%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
6
38
298
2994
7
10
297
3022
—
—
—
—
—
Sleep apnoea
G47.3 [45562094]
6.3e-01
9.2e-01
2.0e+00
—
1.6e+00
2.4e-01
3.2e-01
cases:6.91%
controls:3.79%
cases:4.61%
controls:1.88%
cases:2.96%
controls:0.43%
—
—
cases:2.01%
controls:0.43%
cases:3.08%
controls:2.43%
cases:6.83%
controls:5.06%
21
115
283
2917
14
57
290
2975
9
13
295
3019
—
6
13
293
3008
8
71
252
2855
11
111
150
2083
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
5.9e-01
—
—
—
—
1.9e+00
2.0e-01
cases:4.93%
controls:2.80%
—
—
—
—
—
—
—
—
cases:4.62%
controls:0.68%
cases:3.11%
controls:2.55%
15
85
289
2947
—
—
—
—
12
20
248
2906
5
56
156
2138
digoxin; oral, parenteral
C01AA05 [21600234]
5.9e-01
9.9e-01
1.1e+00
—
1.2e+00
9.5e-01
2.2e-01
cases:7.57%
controls:4.32%
cases:7.89%
controls:3.10%
cases:2.96%
controls:1.06%
—
—
cases:2.01%
controls:0.63%
cases:8.46%
controls:3.45%
cases:6.21%
controls:5.06%
23
131
281
2901
24
94
280
2938
9
32
295
3000
—
6
19
293
3002
22
101
238
2825
10
111
151
2083
insulin aspart; parenteral
A10AB05 [21600719]
9.7e-01
9.6e-01
—
—
—
8.5e-01
8.4e-01
cases:6.58%
controls:2.61%
cases:5.92%
controls:2.34%
—
—
—
—
—
—
cases:6.15%
controls:2.73%
cases:9.32%
controls:4.24%
20
79
284
2953
18
71
286
2961
—
—
—
16
80
244
2846
15
93
146
2101
Potassium [Moles/volume] in Arterial blood
32713-0 [3043409]
1.9e+00
—
—
—
—
2.0e+00
1.4e+00
cases:3.95%
controls:0.59%
—
—
—
—
—
—
—
—
cases:1.92%
controls:0.27%
cases:4.35%
controls:1.09%
12
18
292
3014
—
—
—
—
5
8
255
2918
7
24
154
2170
Other and unspecified convulsions
R56.8 [45602033]
1.8e+00
—
—
—
—
—
1.9e+00
cases:1.97%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:4.97%
controls:0.77%
6
10
298
3022
—
—
—
—
—
8
17
153
2177
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
307 [2001600266]
1.9e+00
1.3e+00
—
—
—
—
6.5e-01
cases:7.57%
controls:1.22%
cases:1.97%
controls:0.56%
—
—
—
—
—
—
—
—
cases:4.35%
controls:2.32%
23
37
281
2995
6
17
298
3015
—
—
—
—
7
51
154
2143
insulin aspart; parenteral
A10AD05 [21600733]
9.4e-01
9.4e-01
—
—
—
8.3e-01
8.1e-01
cases:6.58%
controls:2.67%
cases:5.92%
controls:2.41%
—
—
—
—
—
—
cases:6.15%
controls:2.77%
cases:9.32%
controls:4.38%
20
81
284
2951
18
73
286
2959
—
—
—
16
81
244
2845
15
96
146
2098
Pleural effusion, not elsewhere classified
J90 [45605897]
1.9e+00
—
—
—
—
—
—
cases:2.30%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
297
3021
—
—
—
—
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
7.3e-01
1.1e+00
1.2e+00
—
8.1e-01
6.0e-01
6.8e-03
cases:22.70%
controls:12.40%
cases:18.75%
controls:6.93%
cases:3.29%
controls:0.99%
—
—
cases:3.34%
controls:1.52%
cases:13.08%
controls:7.62%
cases:18.01%
controls:17.91%
69
376
235
2656
57
210
247
2822
10
30
294
3002
—
10
46
289
2975
34
223
226
2703
29
393
132
1801
methenamine; oral
J01XX05 [21603065]
7.4e-01
—
—
—
—
—
1.8e+00
cases:1.64%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
cases:6.83%
controls:1.14%
5
24
299
3008
—
—
—
—
—
11
25
150
2169
Intravenous administration of medicine
SPAT1255 [2001700356]
1.8e+00
1.8e+00
—
—
—
—
1.7e+00
cases:2.63%
controls:0.43%
cases:1.97%
controls:0.33%
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.82%
8
13
296
3019
6
10
298
3022
—
—
—
—
7
18
154
2176
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
6.5e-01
8.7e-01
1.8e+00
—
1.1e+00
3.3e-01
1.7e-01
cases:6.25%
controls:3.36%
cases:4.61%
controls:1.98%
cases:2.63%
controls:0.43%
—
—
cases:1.67%
controls:0.56%
cases:3.08%
controls:2.22%
cases:4.97%
controls:4.24%
19
102
285
2930
14
60
290
2972
8
13
296
3019
—
5
17
294
3004
8
65
252
2861
8
93
153
2101
Unspecified haematuria
R31 [45553726]
6.2e-01
1.5e+00
—
—
—
1.8e+00
4.7e-01
cases:3.62%
controls:1.98%
cases:2.63%
controls:0.59%
—
—
—
—
—
—
cases:3.08%
controls:0.51%
cases:3.73%
controls:2.37%
11
60
293
2972
8
18
296
3014
—
—
—
8
15
252
2911
6
52
155
2142
Procalcitonin [Mass/volume] in Serum or Plasma
33959-8 [3046279]
—
1.8e+00
—
—
—
—
9.8e-01
—
—
cases:2.96%
controls:0.49%
—
—
—
—
—
—
—
—
cases:3.11%
controls:1.19%
—
9
15
295
3017
—
—
—
—
5
26
156
2168
General health counselling
SPAT1312 [2001700413]
6.5e-01
4.9e-01
—
—
—
1.1e+00
5.0e-01
cases:11.84%
controls:6.53%
cases:4.61%
controls:2.87%
—
—
—
—
—
—
cases:6.15%
controls:2.05%
cases:9.94%
controls:6.29%
36
198
268
2834
14
87
290
2945
—
—
—
16
60
244
2866
16
138
145
2056
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
1.8e+00
1.8e+00
—
—
—
-1.0e+50
—
cases:2.30%
controls:0.40%
cases:1.64%
controls:0.26%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
7
12
297
3020
5
8
299
3024
—
—
—
0
10
260
2916
—
Malignant tumour
130 [2001600128]
1.8e+00
—
—
—
—
-1.0e+50
-1.0e+50
cases:2.30%
controls:0.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:1.19%
7
12
297
3020
—
—
—
—
0
7
260
2919
0
26
161
2168
Lactate [Moles/volume] in Arterial blood
2518-9 [3018405]
1.8e+00
—
—
—
—
1.6e+00
1.3e+00
cases:3.95%
controls:0.69%
—
—
—
—
—
—
—
—
cases:1.92%
controls:0.38%
cases:4.35%
controls:1.19%
12
21
292
3011
—
—
—
—
5
11
255
2915
7
26
154
2168
dexamethasone; oral, parenteral
H02AB02 [21602730]
9.4e-01
1.8e+00
—
—
—
—
—
cases:4.61%
controls:1.85%
cases:4.28%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
14
56
290
2976
13
23
291
3009
—
—
—
—
—
Alzheimer disease
G30 [45538101]
1.7e+00
1.2e+00
—
—
—
—
—
cases:5.92%
controls:1.12%
cases:1.97%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
18
34
286
2998
6
18
298
3014
—
—
—
—
—
Oedema, unspecified
R60.9 [45568143]
1.7e+00
—
—
—
—
-1.0e+50
—
cases:2.96%
controls:0.56%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
9
17
295
3015
—
—
—
—
0
11
260
2915
—
Bacterial infection, unspecified
A49.9 [45590816]
8.4e-01
1.7e+00
—
—
—
—
1.1e+00
cases:3.29%
controls:1.45%
cases:3.62%
controls:0.69%
—
—
—
—
—
—
—
—
cases:7.45%
controls:2.55%
10
44
294
2988
11
21
293
3011
—
—
—
—
12
56
149
2138
Erysipelas
A46 [45561706]
7.1e-01
1.6e+00
—
—
—
1.2e+00
4.9e-01
cases:5.26%
controls:2.67%
cases:4.28%
controls:0.86%
—
—
—
—
—
—
cases:2.31%
controls:0.72%
cases:5.59%
controls:3.51%
16
81
288
2951
13
26
291
3006
—
—
—
6
21
254
2905
9
77
152
2117
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
1.6e+00
—
—
—
—
—
—
cases:2.96%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
9
18
295
3014
—
—
—
—
—
—
bimatoprost
S01EE03 [21603712]
1.6e+00
1.5e+00
—
—
—
1.6e+00
—
cases:2.96%
controls:0.59%
cases:2.30%
controls:0.53%
—
—
—
—
—
—
cases:2.31%
controls:0.48%
—
—
9
18
295
3014
7
16
297
3016
—
—
—
6
14
254
2912
—
Urgent procedure
ZXD05 [2001311386]
5.1e-01
1.6e+00
—
—
—
—
5.3e-01
cases:7.89%
controls:4.88%
cases:5.26%
controls:1.09%
—
—
—
—
—
—
—
—
cases:6.83%
controls:4.15%
24
148
280
2884
16
33
288
2999
—
—
—
—
11
91
150
2103
Photography of fundus of the eye or interpretation of photograph
SPAT1008 [2001700109]
1.6e+00
1.7e+00
—
—
—
1.6e+00
—
cases:5.26%
controls:1.12%
cases:1.97%
controls:0.36%
—
—
—
—
—
—
cases:1.92%
controls:0.41%
—
—
16
34
288
2998
6
11
298
3021
—
—
—
5
12
255
2914
—
cisapride; oral, rectal
A03FA02 [21600485]
1.6e+00
—
—
—
—
—
—
cases:2.96%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
9
19
295
3013
—
—
—
—
—
—
No procedures
SPAT1301 [2001700402]
3.6e-01
7.0e-01
8.2e-01
—
1.5e+00
8.1e-01
3.3e-01
cases:10.20%
controls:7.35%
cases:6.25%
controls:3.20%
cases:2.30%
controls:1.02%
—
—
cases:3.01%
controls:0.66%
cases:7.31%
controls:3.38%
cases:12.42%
controls:9.25%
31
223
273
2809
19
97
285
2935
7
31
297
3001
—
9
20
290
3001
19
99
241
2827
20
203
141
1991
sulfadiazine and trimethoprim
J01EE02 [21602962]
7.2e-01
1.5e+00
—
—
—
—
8.4e-01
cases:7.57%
controls:3.83%
cases:3.29%
controls:0.73%
—
—
—
—
—
—
—
—
cases:6.21%
controls:2.78%
23
116
281
2916
10
22
294
3010
—
—
—
—
10
61
151
2133
fluoxetine; oral
N06AB03 [21604711]
1.5e+00
1.6e+00
—
—
—
—
—
cases:2.96%
controls:0.66%
cases:1.64%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
9
20
295
3012
5
10
299
3022
—
—
—
—
—
ABO and Rh group [Type] in Blood
882-1 [3003694]
6.5e-01
1.5e+00
—
—
—
7.4e-01
-5.5e-01
cases:6.91%
controls:3.73%
cases:3.95%
controls:0.89%
—
—
—
—
—
—
cases:1.92%
controls:0.92%
cases:3.11%
controls:5.24%
21
113
283
2919
12
27
292
3005
—
—
—
5
27
255
2899
5
115
156
2079
solifenacin; oral
G04BD08 [21602641]
1.5e+00
1.5e+00
—
—
—
—
8.0e-01
cases:3.29%
controls:0.76%
cases:1.97%
controls:0.46%
—
—
—
—
—
—
—
—
cases:3.11%
controls:1.41%
10
23
294
3009
6
14
298
3018
—
—
—
—
5
31
156
2163
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
1.5e+00
7.0e-01
—
—
—
1.1e+00
1.0e+00
cases:4.61%
controls:1.09%
cases:1.64%
controls:0.82%
—
—
—
—
—
—
cases:3.08%
controls:1.03%
cases:6.83%
controls:2.60%
14
33
290
2999
5
25
299
3007
—
—
—
8
30
252
2896
11
57
150
2137
oxybutynin; oral, transdermal
G04BD04 [21602637]
1.4e+00
1.7e+00
—
—
—
—
1.6e+00
cases:3.29%
controls:0.79%
cases:1.97%
controls:0.36%
—
—
—
—
—
—
—
—
cases:3.11%
controls:0.64%
10
24
294
3008
6
11
298
3021
—
—
—
—
5
14
156
2180
Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]
1.4e+00
—
—
—
—
-1.0e+50
—
cases:3.62%
controls:0.89%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
11
27
293
3005
—
—
—
—
0
7
260
2919
—
Syncope and collapse
R55 [45568141]
1.4e+00
1.3e+00
—
—
—
—
9.7e-02
cases:6.58%
controls:1.68%
cases:2.63%
controls:0.73%
—
—
—
—
—
—
—
—
cases:3.11%
controls:2.83%
20
51
284
2981
8
22
296
3010
—
—
—
—
5
62
156
2132
erdosteine; oral
R05CB15 [21603394]
6.3e-01
1.4e+00
—
—
—
1.2e+00
-7.1e-02
cases:4.61%
controls:2.51%
cases:3.95%
controls:0.99%
—
—
—
—
—
—
cases:4.23%
controls:1.30%
cases:3.11%
controls:3.33%
14
76
290
2956
12
30
292
3002
—
—
—
11
38
249
2888
5
73
156
2121
Sampling
SPAT1263 [2001700364]
3.2e-02
7.2e-01
1.4e+00
—
1.2e+00
7.4e-01
5.2e-01
cases:10.53%
controls:10.22%
cases:8.55%
controls:4.35%
cases:3.29%
controls:0.82%
—
—
cases:2.68%
controls:0.79%
cases:8.08%
controls:4.03%
cases:14.91%
controls:9.43%
32
310
272
2722
26
132
278
2900
10
25
294
3007
—
8
24
291
2997
21
118
239
2808
24
207
137
1987
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
7.7e-01
1.4e+00
—
—
—
5.6e-01
2.1e-01
cases:6.25%
controls:3.00%
cases:5.59%
controls:1.45%
—
—
—
—
—
—
cases:3.08%
controls:1.78%
cases:4.97%
controls:4.06%
19
91
285
2941
17
44
287
2988
—
—
—
8
52
252
2874
8
89
153
2105

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
99
190
7.21
53.16
8.1
3.0
6.10
6.17
ph
0.29
92
150
72
167
5.33
30.48
6.0
4.0
—
—
—
0
0
42
57
8.38
30.04
7.6
5.3
11.45
11.29
mmol/l
0.09
42
48
42
57
8.38
30.04
7.6
5.3
103.31
104.42
mmol/l
0.59
42
48
89
255
4.51
29.01
6.5
8.1
122.06
119.70
g/l
0.55
89
246
74
185
4.95
28.57
6.4
5.9
25.54
24.26
mmol/l
1.82
74
173
92
282
4.23
27.26
6.8
7.7
95.82
95.00
%
0.78
92
269
131
548
3.43
24.02
9.7
5.0
1.02
1.02
kg/l
0.24
108
363
93
318
3.76
23.23
7.3
7.2
7.42
7.41
ph
0.38
77
181
92
321
3.66
22.20
7.3
7.1
11.42
11.44
kpa
0.01
92
301
92
321
3.66
22.20
7.3
7.1
5.19
5.09
kpa
0.43
92
301
91
322
3.60
21.41
7.4
7.1
2.55
0.95
mmol/l
5.19
82
262
139
637
3.16
21.39
8.7
4.7
0.00
0.01
estimate
0.50
14
186
46
111
4.70
18.17
7.6
4.6
2.07
1.57
%
2.56
46
99
45
109
4.67
17.68
7.8
4.6
1.02
0.92
%
1.02
45
98
144
781
2.59
14.81
6.6
3.6
—
—
—
0
0
136
730
2.55
14.15
6.3
4.4
—
—
—
0
0
145
865
2.28
11.25
10.0
4.6
0.00
0.07
estimate
1.47
14
175
67
292
2.66
10.32
2.4
1.7
—
—
—
0
0
108
599
2.24
9.69
10.3
3.8
0.00
0.18
estimate
0.58
14
158
169
1139
2.08
8.96
9.4
4.4
0.00
1.50
estimate
0.50
18
200
95
519
2.20
8.71
2.1
1.8
410.78
27857580.06
pmol/l
0.50
90
420
166
1122
2.04
8.61
9.6
4.5
0.00
0.00
estimate
-0.00
17
213
166
1133
2.01
8.26
9.5
4.5
0.00
7.42
estimate
0.50
18
219
86
472
2.14
7.68
3.9
3.1
517.74
541.64
mosm/kgh2o
0.51
80
407
178
1317
1.84
6.27
10.4
5.4
7.25
6.84
mmol/l
1.46
178
1240
63
332
2.13
6.14
3.1
1.9
—
—
—
0
0
138
953
1.81
6.03
5.9
4.7
63.11
48.61
ng/l
0.30
118
737
17
34
5.23
5.97
2.1
1.5
—
—
—
0
0
27
621
0.38
5.74
3.4
3.5
—
—
—
0
0
194
1498
1.80
5.69
9.9
5.4
9122.80
2197.22
e6/l
—
5
46
83
522
1.81
4.75
2.0
1.8
1135.14
1114.28
nmol/l
0.11
71
389
17
55
3.21
4.43
4.6
3.5
—
—
—
0
0
22
83
2.78
4.43
12.3
3.0
25.77
24.89
mmol/l
0.40
22
83
104
715
1.69
4.30
6.7
4.3
7.41
7.39
ph
1.70
86
529
153
1170
1.61
4.11
11.7
7.0
1.21
1.21
mmol/l
0.15
142
967
8
10
8.18
4.08
1.1
1.0
91.63
107.50
pmol/l
—
8
10
16
58
2.86
3.48
1.6
1.4
241.73
352.01
ug/g
1.31
11
33
137
1051
1.55
3.45
6.7
5.1
33.76
34.45
g/l
0.69
130
963
106
778
1.55
3.21
5.3
3.6
86.67
136.97
e6/l
0.23
95
623
96
693
1.56
3.11
2.6
2.4
2.67
3.16
mg/l
1.06
91
592
181
1498
1.51
3.07
9.6
4.9
—
2.87
—
0
7
8
18
4.53
2.81
2.9
1.9
—
—
—
0
0
73
506
1.58
2.79
5.4
4.0
64.53
304.97
ng/l
2.66
63
448
5
6
8.44
2.76
1.4
1.0
—
—
—
0
0
113
864
1.49
2.75
6.1
4.1
191.01
191.60
e6/l
0.00
97
645
7
14
5.09
2.74
1.1
1.7
—
—
—
0
0
27
142
1.99
2.65
2.9
3.3
0.82
0.93
%
0.12
22
61
92
685
1.49
2.52
2.5
2.4
—
—
—
0
0
96
723
1.48
2.48
7.5
5.8
—
—
—
0
0
9
30
3.06
2.16
2.6
2.8
561.67
479.30
mg
—
9
30
24
131
1.90
2.15
2.6
3.2
0.97
0.53
%
0.57
19
53
19
97
2.02
2.05
1.4
1.3
—
—
—
0
0
41
268
1.61
2.00
4.6
5.1
7.38
7.37
ph
0.37
25
175
40
260
1.62
2.00
1.5
1.3
—
—
—
0
0
68
499
1.47
1.97
1.4
1.3
—
—
—
0
0
11
45
2.50
1.95
1.6
1.6
18.11
25.09
iu/l
0.42
11
36
30
184
1.70
1.87
3.4
2.8
—
—
—
0
0
33
208
1.66
1.86
1.8
2.3
192.36
131.44
ug/g
0.57
28
157
139
1170
1.34
1.78
25.2
19.2
1.40
1.37
inr
0.21
127
974
116
952
1.35
1.75
3.2
2.8
—
—
estimate
—
0
0
8
30
2.71
1.73
2.8
2.3
90.40
88.86
%
—
8
30
65
843
0.71
1.67
19.4
11.9
0.00
0.00
e9/l
0.45
53
683
6
19
3.20
1.67
1.2
1.4
19.48
38.45
ng/l
—
6
19
28
175
1.66
1.64
1.4
1.6
—
—
—
0
0
172
1928
0.75
1.64
5.5
5.9
2.38
2.51
mmol/l
1.23
164
1722
179
1576
1.33
1.64
46.2
23.3
14.34
13.95
%
3.12
179
1551
13
63
2.11
1.62
1.6
1.6
—
—
—
0
0
165
1858
0.76
1.61
4.9
5.1
1.32
1.43
mmol/l
2.87
156
1651
33
484
0.64
1.61
2.4
3.2
1.00
0.83
ug/l
0.38
27
321
31
201
1.60
1.59
1.5
1.5
—
—
—
0
0
111
921
1.32
1.52
6.1
4.1
6.32
6.22
ph
0.40
73
518
19
110
1.78
1.46
3.2
3.0
—
—
—
0
0
9
178
0.49
1.45
1.2
1.4
—
—
—
0
0
168
1874
0.77
1.44
5.0
5.2
4.16
4.39
mmol/l
2.09
158
1685
5
16
3.16
1.44
1.4
1.3
—
—
—
0
0
37
260
1.48
1.35
3.9
5.1
1.57
1.72
mmol/l
0.08
30
206
0
39
0.00
1.34
0.0
1.2
—
0.67
—
0
9
21
130
1.66
1.30
2.5
2.6
—
—
—
0
0
5
18
2.81
1.29
1.0
1.2
—
—
—
0
0
8
37
2.19
1.22
1.4
1.4
—
—
—
0
0
32
224
1.48
1.20
3.1
4.2
4.24
4.33
kpa
0.10
27
212
136
1189
1.26
1.19
14.8
9.0
5.19
4.45
e9/l
1.68
123
1033
161
1780
0.80
1.15
4.5
4.4
1.38
1.25
mmol/l
1.43
153
1566
0
36
0.00
1.14
0.0
1.4
—
—
—
0
0
173
1892
0.80
1.09
5.1
5.4
6.28
6.08
mmol/l
0.85
165
1666
6
123
0.48
1.07
12.2
3.9
—
—
—
0
0
51
641
0.75
1.04
7.3
5.8
—
—
—
0
0
31
223
1.43
1.03
8.5
8.6
1.46
1.39
mmol/l
0.14
31
218
7
34
2.08
1.03
1.6
1.2
—
—
—
0
0
53
418
1.32
1.03
5.4
4.5
—
—
—
0
0
29
207
1.44
1.01
5.1
3.6
—
—
—
0
0
6
28
2.16
0.92
1.2
2.8
—
—
—
0
0
7
127
0.54
0.90
1.9
1.4
—
—
—
0
0
10
168
0.58
0.89
1.8
1.6
—
—
—
0
0
6
30
2.02
0.87
11.0
3.5
10.00
12.58
pmol/l
—
6
30
6
30
2.02
0.87
1.8
2.3
32.50
32.37
pg
—
6
30
215
2018
1.22
0.84
37.2
18.5
32.69
28.90
mg/l
0.92
207
1699
50
404
1.28
0.83
3.6
2.6
2.43
2.22
g/l
1.31
50
364
30
225
1.37
0.82
8.7
9.3
—
—
—
0
0
120
1070
1.20
0.81
7.9
5.5
0.67
0.62
e9/l
0.89
108
905
110
973
1.20
0.81
7.5
5.6
59.36
59.55
%
0.05
110
914
33
255
1.33
0.76
2.0
2.9
62.97
63.75
e9/l
0.05
27
204
120
1076
1.19
0.75
8.0
5.5
0.04
0.04
e9/l
0.27
108
916
9
55
1.66
0.74
1.2
1.3
64.22
61.16
mmol/l
—
9
43
6
110
0.54
0.73
2.7
2.0
—
—
—
0
0
7
40
1.77
0.71
1.6
2.4
0.80
0.97
%
—
7
29
5
27
1.87
0.68
2.6
3.1
—
—
—
0
0
6
105
0.56
0.63
1.0
1.3
—
—
—
0
0
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
—
—
0
0
28
220
1.30
0.59
1.3
1.2
—
—
—
0
0
18
132
1.39
0.58
3.2
3.3
0.00
0.25
%
0.82
13
53
85
758
1.17
0.56
2.7
2.3
—
—
—
0
0
63
550
1.18
0.53
2.7
3.0
351.74
362.37
umol/l
0.28
58
467
79
703
1.17
0.53
2.0
1.8
20.07
20.23
nmol/l
0.03
73
570
6
100
0.59
0.52
11.5
4.4
25.17
25.66
mmol/l
—
6
93
9
64
1.42
0.52
1.3
1.2
—
—
—
0
0
43
364
1.21
0.51
1.7
1.4
2.34
2.67
g/l
0.55
26
193
18
136
1.34
0.50
1.3
1.1
—
—
—
0
0
7
45
1.57
0.49
1.9
1.3
—
—
—
0
0
7
45
1.57
0.49
6.1
2.7
15.43
15.49
%
—
7
45
7
45
1.57
0.49
1.9
1.3
—
—
—
0
0
7
46
1.53
0.48
1.9
1.3
—
—
—
0
0
7
46
1.53
0.48
1.9
1.3
—
—
—
0
0
119
1103
1.13
0.45
8.0
5.8
0.19
0.19
e9/l
0.01
107
946
5
31
1.62
0.43
4.0
3.0
17.40
40.87
u/ml
—
5
31
0
15
0.00
0.41
0.0
2.7
—
33.13
—
0
15
0
16
0.00
0.41
0.0
1.5
—
—
—
0
0
8
61
1.32
0.40
1.3
1.2
—
3.56
—
0
5
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
2.2
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
10
72
1.40
0.37
5.4
4.6
2.07
1.78
mg/l
—
10
56
10
135
0.73
0.37
4.9
3.3
0.00
0.11
%
—
5
53
212
2047
1.12
0.36
38.0
17.2
—
—
—
0
0
6
42
1.44
0.35
1.0
1.1
22.88
35.42
u/l
—
6
36
14
178
0.78
0.35
10.6
4.2
—
—
—
0
0
20
163
1.24
0.35
11.3
9.3
25.68
24.48
mmol/l
1.00
20
155
27
229
1.20
0.33
2.0
1.4
—
—
—
0
0
32
276
1.18
0.33
2.7
4.1
5.05
47.18
ug/l
0.90
24
240
6
47
1.28
0.32
1.7
1.3
—
—
—
0
0
61
667
0.89
0.30
6.5
3.5
0.69
0.44
e6/l
0.51
50
515
12
93
1.30
0.30
1.4
1.2
149.98
125.85
u/ml
—
6
39
28
242
1.17
0.29
2.0
1.7
—
—
—
0
0
23
269
0.84
0.29
1.6
1.4
—
—
—
0
0
14
113
1.25
0.27
3.9
3.3
25.64
24.57
mmol/l
0.71
14
106
13
160
0.80
0.26
18.1
4.1
1.17
1.22
mmol/l
1.31
13
136
110
1047
1.08
0.23
2.2
2.3
87.60
91.59
pmol/l
0.52
73
552
0
11
0.00
0.21
0.0
2.5
—
5.61
—
0
11
0
12
0.00
0.21
0.0
1.0
—
174.57
—
0
12
155
1501
1.07
0.20
4.7
3.8
14.90
15.16
pmol/l
0.62
146
1301
44
405
1.10
0.20
1.5
1.2
3.87
2.08
u/ml
—
9
95
114
1093
1.07
0.20
8.1
5.6
1.69
1.77
e9/l
0.54
104
958
12
100
1.21
0.18
1.1
1.3
—
38.79
—
0
9
13
111
1.18
0.16
2.1
2.6
—
11.93
—
0
7
9
78
1.16
0.15
6.1
11.7
—
—
—
0
0
75
718
1.06
0.13
3.3
3.2
76.65
52.69
mg/l
0.47
60
482
125
1215
1.05
0.13
3.8
3.3
56.97
55.41
u/l
0.07
117
1118
25
272
0.91
0.12
1.6
1.2
0.97
9.53
u/ml
—
6
81
5
45
1.11
0.10
1.0
1.3
968.00
334.50
pmol/l
—
5
45
46
479
0.95
0.08
1.5
1.8
1.29
1.55
mg/l
0.45
35
388
180
1823
0.97
0.07
6.0
4.9
2.02
2.04
mu/l
0.07
171
1598
32
309
1.04
0.04
1.3
1.3
11.40
37.60
iu/ml
3.43
13
97
73
737
0.99
0.01
3.8
3.9
19.68
9.84
mg/mmol
1.01
45
468
11
104
1.06
0.01
1.5
1.3
241.73
179.40
u/ml
0.14
11
94
12
114
1.05
0.01
1.1
1.4
—
—
—
0
0
36
362
0.99
0.00
5.8
3.2
1.18
1.72
e6/l
0.33
18
195
5
52
0.96
0.00
1.2
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
18.80
—
0
7
0
5
0.00
-0.00
0.0
1.4
—
6.38
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
0.00
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.0
—
1.00
—
0
5
0
8
0.00
-0.00
0.0
2.9
—
1950.00
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
9
90
1.00
-0.00
1.8
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
5.0
—
6.94
—
0
7

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: Z21_PROBL_RELATED_CARE__DEPENDENCY – Problems related to care-provider dependency

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).